Review

Anti-Viral and Immunomodulatory Properties of Propolis: Chemical Diversity, Pharmacological Properties, Preclinical and Clinical Applications, and In Silico Potential against SARS-CoV-2

Nermeen Yosri 1,2, Aida A. Abd El-Wahed 3, Reem Ghonaim 2, Omar M. Khattab 2, Aya Sabry 2, Mahmoud A. A. Ibrahim 4, Mahmoud F. Moustafa 5,6, Zhiming Guo 1, Xiaobo Zou 1, Ahmed F. M. Algethami 7, Saad H. D. Masry 8,9, Mohamed F. AlAjmi 10, Hanan S. Afifi 11, Shaden A. M. Khalifa 12,* and Hesham R. El-Seedi 2,13,14,*

School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China; nermeen.yosri@science.menofia.edu.eg (N.Y.); guozhiming@ujs.edu.cn (Z.G.); zou_xiaobo@ujs.edu.cn (X.Z.)
2 Department of Chemistry, Faculty of Science, Menoufia University, Shebin El-Kom 32512, Egypt; reemghoniem222@gmail.com (R.G.); omarkhattab500@gmail.com (O.M.K.); ayasabry816@yahoo.com (A.S.)
3 Department of Bee Protection, Plant Protection Research Institute, Agricultural Research Centre, Giza 12627, Egypt; alaabedm.ELWahed@arc.sci.eg
4 Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt; m.ibrahim@compchem.net
5 Department of Biology, College of Science, King Khalid University, Abha 9004, Saudi Arabia; hamdony@yahoo.com
6 Department of Botany & Microbiology, Faculty of Science, South Valley University, Qena 83523, Egypt
7 Alnahalaljwal Foundation Saudi Arabia, P.O. Box 617, Al Jumum 21926, Saudi Arabia; ahmed@alnahalaljwal.com.sa
8 Department of Plant Protection and Biomolecular Diagnosis, Arid Lands Cultivation Research Institute (ALCRI), City of Scientific Research and Technological Applications, New Borg El-Arab City, Alexandria 21934, Egypt; saad.masry@adafsa.gov.ae
9 Abu Dhabi Agriculture and Food Safety Authority (ADAFSA), Al Ain 52150, United Arab Emirates
10 Pharmacognosy Group, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; malajmi@ksu.edu.sa
11 Food Research Section, R&D Division, Abu Dhabi Agriculture and Food Safety Authority (ADAFSA), Abu Dhabi P.O. Box 52150, United Arab Emirates; hanan.afifi@adafsa.gov.ae
12 Department of Molecular Biosciences, Stockholm University, The Wenner-Gren Institute, SE-106 91 Stockholm, Sweden
13 International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang 212013, China
14 Division of Pharmacognosy, Department of Pharmaceutical Biosciences, Uppsala University, Biomedical Centre, P.O. Box 591, SE 751 24 Uppsala, Sweden
* Correspondence: shaden.khalifa@su.se (S.A.M.K.); hesham.el-seedi@farmbio.uu.se (H.R.E.-S.); Tel.: +46-700-101-113 (S.A.M.K.); +46-700-434-343 (H.R.E.-S.)

Abstract: Propolis, a resin produced by honeybees, has long been used as a dietary supplement and folk remedy, and more recent preclinical investigations have demonstrated a large spectrum of potential therapeutic bioactivities, including antioxidant, antibacterial, anti-inflammatory, neuroprotective, immunomodulatory, anticancer, and antiviral properties. As an antiviral agent, propolis and various constituents have shown promising preclinical efficacy against adenoviruses, influenza viruses, respiratory tract viruses, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), human immunodeficiency virus (HIV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Over 300 chemical components have been identified in propolis, including terpenes, flavonoids, and phenolic acids, with the specific constituent profile varying widely according to geographic origin and regional flora. Propolis and its constituents have demonstrated potential efficacy against SARS-CoV-2 by modulating multiple pathogenic and antiviral pathways. Molecular docking studies have demonstrated high binding affinities of propolis derivatives to multiple SARS-CoV-2 proteins, including 3C-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase (RdRp), the receptor-binding domain (RBD) of the spike protein (S-protein), and helicase (NSP13), as well as to the viral target angiotensin-converting enzyme 2 (ACE2). Among these compounds, retusapurpurin A has shown high affinity to 3CLpro (ΔG = −9.4 kcal/mol), RdRp (−7.5), RBD (−7.2),
NSP13 (−9.4), and ACE2 (−10.4) and potent inhibition of viral entry by forming hydrogen bonds with amino acid residues within viral and human target proteins. In addition, propolis-derived baccharin demonstrated even higher binding affinity towards PLpro (−8.2 kcal/mol). Measures of drug-likeness parameters, including metabolism, distribution, absorption, excretion, and toxicity (ADMET) characteristics, also support the potential of propolis as an effective agent to combat COVID-19.

**Keywords:** propolis; chemical constituents; antiviral; immunomodulatory; clinical applications; SARS-CoV-2; molecular docking

1. Introduction

Propolis is a natural wax-like resin produced by honeybees (*Apis mellifera* L.) consisting of salivary secretions, wax, pollen, and various plant materials. Honeybees use propolis as a cement (bee glue) to seal cracks or open spaces in beehives, thereby preventing invasion by parasites and helping to maintain appropriate internal temperature and humidity [1,2]. The name propolis, from the Greek *pro* for “in defense” and *polis* for “city”, reflects its importance for preventing diseases and parasites from entering the hive and inhibiting putrefaction, fungal growth, and bacterial growth [3]. The beneficial effects of propolis on human health were recognized thousands of years ago, with reports of use in folk medicine dating back to the ancient Egyptians, Greeks, and Romans [4]. In the 17th century, the London pharmacopoeias listed propolis as an official drug [5], further highlighting the ubiquity of propolis as a disease treatment throughout the centuries. In folk medicine, propolis is used for the management of airway disorders and cutaneous-mucosal infection by bacteria and viruses [6]. In some Asian, European, and South American countries, propolis is still used to make health drinks [7]. Additionally, it is used in toothpaste and mouthwash preparations for treating gingivitis, cheilitis, and stomatitis [8,9].

More rigorous laboratory investigations have documented a wide range of biological activities, such as antiseptic, anti-inflammatory, antioxidant, antibacterial, antymycotic, antifungal, antiulcer, anticancer, wound-healing, and immunomodulatory properties [10,11]. Propolis has shown antiviral activity in vitro and (or) in animal models against several DNA and RNA viruses, such as herpes simplex virus type 1 (HSV-1), an acyclovir resistant HSV1 mutant, herpes simplex virus type 2 (HSV-2), adenovirus type 2, vesicular stomatitis virus (VSV), poliovirus type 2 (PV-2) [12,13], avian influenza virus (H7N7) [14], human rhinoviruses (HRVs) [15], influenza viruses A/H1N1 and A/NH3N2 [16], classic coronaviruses [17], and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [18–20]. In general, propolis consists of 50% resin, 30% wax, 10% essential oils, 5% pollen, 2% mineral salts, and an array of nutrients (intermediate metabolites) and bioactive polyphenols, mainly flavonoids, phenolic acids, and various ester and cinnamic acid derivatives [21,22]. Among these include several well described antiviral and immunomodulatory compounds such as kaempferol, *p*-coumaric acid, apigenin, artepillin C, caffeic acid, and caffeic acid phenyl ester [15,23,24].

The main aim of this review is to highlight the potential of propolis and its various constituents and/or derivatives as antiviral and immunomodulatory drugs against infectious diseases, including COVID-19 caused by SARS-CoV-2. Molecular docking analyses have identified over 40 propolis-derived compounds with strong binding affinity to various SARS-CoV-2 proteins and the human viral receptor. Moreover, measurements of drug-likeness parameters such as absorption, distribution, metabolism, excretion, and toxicity (ADMET) further support some of these agents as potential anti-SARS-CoV-2 drug candidates, warranting more extensive preclinical and clinical investigation.
2. Ethnopharmacology

Since ancient times, propolis has been employed by many cultures as a dietary supplement and folk remedy for improving health and managing disease [23,24]. The use of propolis in folk medicine can be traced back to at least 300 BC [25]. The Egyptians are considered the first peoples to use propolis for wound treatment and as an embalming agent [26,27]. In addition, Greek physicians such as Hippocrates, Dioscorides, and Galen; the Roman natural philosopher Pliny the Elder; and Inca healers utilized propolis as an antiseptic, antipyretic disinfectant for cutaneous and buccal infections and wound treatment. Propolis-based treatments were also in wide use in Europe during the 17th century to treat colds, wounds, rheumatism, heart disease, and diabetes [21,28]. According to Hippocrates, propolis may be used to improve health or prevent disease, including gastrointestinal disorders such as gastritis and gastric ulcer [29]. Arabs and Persians also used propolis as a disease treatment and cleansing agent [30].

All over the world, propolis has been used in traditional and folk medicine to prevent and treat many ailments, i.e., colds, wounds, rheumatism, heart disease, and diabetes [28]. Other documented uses include treatment of pharyngitis as well as wounds [31]. Brazilian green propolis is used as an anti-inflammatory, antibacterial, and antulcer treatment in traditional medicine [32]. Administration for the treatment of abscesses and canker sores as well as wounds has also been reported [33]. During the Anglo-Boer War and Second World War, some physicians used propolis to promote tissue regeneration as well as for wound healing and treatment of tuberculosis, lung inflammation, and malnutrition [30]. Propolis with Ashwagandha (Withania sominifera) is used in some traditional medicine systems to boost immune function and prevent or cure various ailments [34].

3. Chemical Composition of Propolis

Propolis is rich in polyphenolic compounds, primarily flavonoids, cinnamic acids, and esters (Figures 1–3). To date, more than 300 compounds have been isolated and identified from propolis extracts such as benzoic acid and derivatives, benzaldehyde derivatives, aliphatic hydrocarbons, saccharides, vitamins, nicotinic acid, pantothenic acid, chalcones, dihydrochalcones, amino acids, esters, minerals, enzymes, ketones, waxy acids, alcohols, and fatty acids [35]. The active constituents of propolis are diverse and vary according to the local plant species [22]. For instance, six flavonoids were isolated and identified in propolis from the southern Urals (Bashkiria): (2S)-5-hydroxy-7-methoxyflavanone (pinostrobin), (2S)-5,4′-dihydroxy-7-methoxyflavanone (sakuranetin), (2S)-5-hydroxy-7,4′-dimethoxyflavanone (sakuranetin-4′-methyl ether), (2S,3R)-3-acetoxy-5,7-dihydroxyflavanone (pinobanksin-3-acetate), 5,7 dihydroxyflavone (chrysin), and 5-hydroxy-7,4′-dimethoxyflavone (apigenin-7,4′ dimethyl ether) (Figure 1) [36].
(A): Flavanones

Pinobanksin-3-acetate

(B): Flavones

Chrysin

Apigenin-7,4’ dimethyl ether

Figure 1. Cont.
Figure 1. Common flavonoid compounds isolated and identified from propolis of *Apis mellifera* L.

Furthermore, two flavonoids (pinocembrin and chrysin) (Figure 1), *trans*-cinnamic acid, and four phenolic cinnamic acid (caffeic acid, *p*-coumaric acid, ferulic acid, and *m*-coumaric acid) (Figure 2), in addition to many volatile compounds, have been identified by high-pressure liquid chromatography with UV detector (HPLC-UV), nuclear magnetic resonance (NMR), and gas chromatography–mass spectrometry (GC–MS) from two propolis samples from two apiaries with different geographical locations in Italy [1]. From 15 Brazilian green propolis samples of different geographically area and botanical source, 47 compounds were tentatively characterized using HPLC-DAD-MS/MS and NMR, including prenylated phenylpropanoids (drupanin, capillartemisin A, 2,2-dimethylchromene-6-propenoic acid, artepillin C, and baccharin) and (*E*)-2,3-dihydroconiferyl *p*-coumarate; flavonoids and isoflavonoids (pratensein, violane, formononetin, vestitone, and biochanin A) (Figure 1); di- and triterpenoids, as well new compounds; and (*E*)-3-[4-hydroxy-3-(2-hydroxy-3-methylbut-3-en-1-yl)-5-(3-methylbut-2-en-1-yl)phenyl] propenoic acid, among other constituents (Figure 3) [2]. The constituent profile also varies according to extraction method. Saito et al. compared conventional (Soxhlet) extraction using ethanol, methanol, water, or hexane as the solvent to supercritical CO$_2$ extraction for two different types of green and red propolis from Brazil and found that methanolic extraction provided superior yield for both propolis types, while fractionation of red propolis ethanolic extract using
supercritical CO2 yielded mixtures with much higher flavonoid content than the original extract [37].

![Chemical structures](image_url)

**Figure 2.** Common cinnamic acid compounds isolated and identified from propolis of *Apis mellifera* L.

**Figure 3.** Common ester and acid compounds isolated and identified from propolis of *Apis mellifera* L.

Dudoit et al. identified 12 distinct compounds (liquiritigenin, calycosin, calycosin (isomer), luteolin, isoliquiritigenin, formononetin, (3S)-vestitol, (3S)-neovestitol, retusapurpurin A, medicarpin, retusapurpurin A (isomer), and biochanin A) in a Brazilian red propolis sample using HPLC-MS and TLC-bioautography (Figure 1). (3S)-Vestitol, (3S)-neovestitol, and medicarpin were the major components, accounting for 45% of all surface-based chromatographic peaks detected [38]. Picolotto et al. identified five additional flavonoid compounds (biochanin A, daidzein, formononetin, isoliquiritigenin, and liquiritigenin) in red propolis samples collected from Alagoas State in northeastern Brazil using ultrafast liquid chromatography-electrospray ionization-microTOF mass spectrometry (UFLC-ESI-QTOF) [26]. An HPLC study of an Italian propolis sample found that the main active constituents were galangin (42.25 mg/g dry propolis, retention time (RT) =12.87 min),
pinocembrin (27.30 mg/g dry propolis, RT = 10.61 min), and caffeic acid phenethyl ester (CAPE) (11.21 mg/g dry propolis, RT = 11.86 min) [31].

Recently, a multi-dynamic extraction system (RP-HPLC–PDA–ESI–MS) was used to identify quercetin, pinobaskin, apigenin, chrysin, pinocembrin, and galangin in nine samples of propolis gathered separately from three different regions of Europe, America, and Asia [22,39]. Various additional extraction methods such as maceration, ultrasonic extraction, and microwave extraction have also shown variable efficacy for the isolation of propolis components. For instance, ultrasonic extraction achieved a higher yield of p-coumaric acid (271.65 mg/g propolis) than microwave extraction or maceration. Other compounds identified by ultrasonic extraction included apigenin, caffeic acid, chrysin, galangin, isorhamnetin, kaempferol, luteolin, myricetin, pinocembrin, rutin, and quercetin [40].

4. Anti-Viral Activity

Propolis has long been used to treat viral infections and more recently tested for efficacy against SARS-CoV-2, the causative pathogen of COVID-19 [41]. Many disease-causing viruses are unresponsive to currently available antiviral drugs and may also evolve into more drug- and vaccine-resistant strains. Thus, it is critical to identify novel candidate antivirals, particularly from natural sources; as such compounds tend to have good safety profiles.

Herpes simplex virus (HSV) types 1 and 2 are believed to be the most prevalent human viral pathogens. HSV-1 primarily infects oral epithelial tissues, leading to watery blisters on the skin or mucosa, while HSV-2 generally infects the genital mucosa and is sexually transmitted. Acyclovir is one of the main antiviral treatments, but resistant strains are common [42]. South Turkey (Hatay) propolis at 25, 50, and 100 µg/mL was reported to suppress the replication of both HSV-1 and HSV-2 with no toxicity on infected cells, and this antiviral effect was synergetic with acyclovir (positive control) [43]. An ethanolic extract of Brazilian green propolis also demonstrated significant in vitro antiviral activity against acyclovir-resistant HSV by inhibiting replication at an early stage of infection [44]. In addition, a Brazilian hydroalcoholic brown propolis extract (HPE) was reported to protect against vaginal lesions and to reduce epidermal and dermal inflammation induced by HSV-2 in female BALB/c mice (Table 1) [45].

Table 1. The effect of propolis as antiviral activity against different viruses.

| Propolis Origin                        | Type of Extract | Antiviral Activities                                                                 | References |
|----------------------------------------|-----------------|--------------------------------------------------------------------------------------|------------|
| South of Turkey (Hatay region)         | 70% Ethanol     | Herpes simplex virus (HSV-1)                                                         | [43]       |
|                                        |                 | Assay: MTT colorimetric and Real-Time PCR                                           |            |
|                                        |                 | Model: HEP-2 cell culture                                                           |            |
|                                        |                 | MIC = 130 µg/mL                                                                     |            |
|                                        |                 | Tested doses: 25, 50, 75, 100, 200, 400, 800, 1600 and 3200 µg/mL                     |            |
|                                        |                 | PC: Acyclovir                                                                       |            |
|                                        |                 | MIC = 65 µg/mL                                                                       |            |
|                                        |                 | NC: Cell cultures without propolis or acyclovir                                     |            |
|                                        |                 | Mode of action: Inhibits the replication after 24 h. (in vitro)                     |            |
|                                        |                 |                                                                                      |            |
|                                        |                 | Herpes simplex virus (HSV-2)                                                         | [43]       |
|                                        |                 | Assay: MTT colorimetric and Real-Time PCR                                           |            |
|                                        |                 | Model: HEP-2 cell culture                                                           |            |
|                                        |                 | MIC = 250 µg/mL                                                                     |            |
|                                        |                 | Tested doses: 25, 50, 75, 100, 200, 400, 800, 1600 and 3200 µg/mL                     |            |
|                                        |                 | PC: Acyclovir                                                                       |            |
|                                        |                 | MIC = 65 µg/mL                                                                       |            |
|                                        |                 | NC: Cell cultures without propolis or acyclovir                                     |            |
|                                        |                 | Mode of action: Inhibits the replication after 48 h. (in vitro)                     |            |
| Propolis Origin                                      | Type of Extract | Antiviral Activities                                                                 | References |
|-----------------------------------------------------|-----------------|--------------------------------------------------------------------------------------|------------|
| Northwestern Parana state, Brazil                   | 70% Ethanol     | Herpes simplex virus 1 (HSV-1)                                                       | [44]       |
|                                                     |                 | Assay: Attachment and penetration; attachment, virucidal, and plaque formation        |            |
|                                                     |                 | Model: Vero cells                                                                     |            |
|                                                     |                 | EC<sub>50</sub> = 3.20 ± 0.14 µg/mL                                                   |            |
|                                                     |                 | EC<sub>50</sub> for attachment and penetration: 1.21 ± 0.14 µg/mL                     |            |
|                                                     |                 | EC<sub>50</sub> for attachment: 0.40 ± 0.07 µg/mL                                     |            |
|                                                     |                 | EC<sub>50</sub> for virucidal: 3.84 ± 0.15 µg/mL                                      |            |
|                                                     |                 | PC: Acyclovir                                                                          |            |
|                                                     |                 | EC<sub>50</sub> = 1.33 ± 0.08 µg/mL                                                   |            |
|                                                     |                 | NC: Untreated cells                                                                    |            |
|                                                     |                 | Mode of action: Inhibits viral infection and induces virion damage.                   | (in vitro) |
| Santa Flora City (RS-Brazil)                        | 70% Ethanol     | Herpes simplex virus 2 (HSV-2)                                                       | [45]       |
|                                                     |                 | Assay: Plaque reduction                                                                |            |
|                                                     |                 | Model: Female BALB/c mice                                                              |            |
|                                                     |                 | Dose of Pre-treatment: 50 mg/kg, once a day                                           |            |
|                                                     |                 | Dose of Post-treatment: 50 mg/kg for 5 days more                                      |            |
|                                                     |                 | PC: Not reported                                                                       |            |
|                                                     |                 | NC: Untreated cells                                                                    |            |
|                                                     |                 | Mode of action: Reduces extravaginal lesions and the histological damage caused by HSV-2 infection in vaginal tissues of animals. | (in vivo and ex vivo) |
| Moravia, Czech Republic                             | Aqueous extract (15% ethanol) 90% Ethanol | Herpes simplex virus 1 (HSV-1)                                                       | [13]       |
|                                                     |                 | Assay: Plaque reduction                                                                |            |
|                                                     |                 | Model: RC-37 cells                                                                    |            |
|                                                     |                 | Aqueous extract: TC<sub>50</sub> (%): 0.04; IC<sub>50</sub> (%): 0.0004; SI: 100      |            |
|                                                     |                 | Ethanol extract: TC<sub>50</sub> (%)0.0017; IC<sub>50</sub> (%) 0.000035; SI: 485     |            |
|                                                     |                 | PC: Heparin-Na and acyclovir                                                          |            |
|                                                     |                 | NC: Untreated cells                                                                    |            |
|                                                     |                 | Mode of action: Mask viral compounds which are necessary for adsorption or entry into host cells. | (in vitro) |
| Moravia, Czech Republic                             | Aqueous extract (15% ethanol) 90% Ethanol | Herpes simplex virus type 2 (HSV-2)                                                   | [46]       |
|                                                     |                 | Assay: Plaque reduction                                                                |            |
|                                                     |                 | Model: RC-37 cells                                                                    |            |
|                                                     |                 | IC<sub>50</sub>% for aqueous extract: 0.0005; SI: 80                                 |            |
|                                                     |                 | IC<sub>50</sub>% for ethanolic extract: 0.0004; SI: 42.5                              |            |
|                                                     |                 | PC: Acyclovir                                                                          |            |
|                                                     |                 | Inhibits replication of 98.8%                                                         |            |
|                                                     |                 | NC: Untreated cells                                                                    |            |
|                                                     |                 | Mod of action:                                                                       |            |
|                                                     |                 | - Suppresses HSV multiplication;                                                      |            |
|                                                     |                 | - Masks viral compounds which are necessary for adsorption or entry into host cells. | (in vitro) |
|                                                     |                 | (in vitro)                                                                             |            |
| Propolis Origin                  | Type of Extract | Antiviral Activities                                                                                                                                                                                                                                                                                                                                                   | References |
|---------------------------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Canada                          | 70% Ethanol     | **Herpes simplex virus 1 and 2**<br>Assay: Virucidal assay<br>Model: MDBK cell<br>PPE marked effect: 3.2 mg/mL<br>PC: Acyclovir<br>NC: Not reported<br>Mode of action:<br>- Propolis had a pronounced virucidal effect against herpes simplex viruses type 1 and type 2, and also interfered with virus adsorption;<br>- Suppresses the adsorption of HSV-1 at a broad scope of the viral inoculation. (in vitro) | [47]       |
| Botucatu, Brazil                | 70% Ethanol     | **Poliovirus type 1 (PV1)**<br>Assay: Real-time PCR<br>Model: HEP-2 cells<br>- Pre-treatment: 10.9%<br>- Simultaneous treatment: 52.2%<br>- Post-treatment: 39.1%<br>Propolis conc: 5, 10, 25, 50, and 100 µg<br>PC: Cells with virus but without propolis<br>NC: Not reported<br>Mode of action: Causes RNA degradation before the virus entry into cells; also affects the steps of viral cycle replication into cells. (in vitro) | [48]       |
| Rennes (France)                 | 80% Ethanol     | **Poliovirus type 2 (PV), vesicular stomatitis virus (VSV), adenovirus type 2 (Adeno-2), herpes simplex Virus (HSV-1, HSV1-R, and HSV-2)**<br>Assay: Plaque reduction<br>Model: Vero cells<br>Dose: 30 µg/mL<br>PC: NR<br>NC: Without propolis<br>Mode of action: NR (In vitro)                                                                                      | [12]       |
| Moravia, Czech Republic         | 90% Ethanol     | **Varicella zoster virus (VZV)**<br>Assay: Plaque reduction and PCR<br>Model: Cell line of human embryonic lung fibroblasts (LEP)<br>IC_{50}: 64 µg/mL<br>Tested doses: 100 µg/mL<br>PC: Acyclovir (conc: 50 µg/mL)<br>NC: Untreated culture<br>Mode of action: Masking viral compounds which are necessary for entry into host cells. (in vitro) | [49]       |
| Paraná state and Alagoas state, Brazil | 80% Ethanol | **Enterovirus surrogates**<br>MS2 and Av-08 bacteriophage<br>Assay: Plaque formation<br>Tested conc.: 100, 500, and 1000 µg/mL<br>PC: Not reported<br>NC: Bacteriophage with 1 mL of *E. coli* O157 bacteria without the addition of the propolis extracts<br>Mode of action: Inhibits viral polymerase and the binding of viral nucleic acid or capsid proteins. (in vitro) | [50]       |
| Propolis Origin                  | Type of Extract | Antiviral Activities                                                                 | References |
|---------------------------------|-----------------|---------------------------------------------------------------------------------------|------------|
| Tavarnelle Val di Pesa, Firenze, Italy | 80% Ethanol     | Influenza A virus H1N1 Model: Madin-Darby canine kidney cells (MDCK) Anti-neuraminidase IC₅₀ (µg/mL): 35.29 ± 4.08 PC: Oseltamivir IC₅₀ (µg/mL): 5.88 ± 0.89 NC: Not reported Mode of action:  - Inhibits viral growth; - Inhibits neuraminidase (NA) activity. (in vitro) | [31]       |
| Brazil and China                | 95% Ethanol     | Human immunodeficiency virus type 1 (HIV-1) Model: CD4⁺ lymphocytes and microglial cell cultures At 66.6 µg/mL give inhibition 85 and 98% PC: Zidovudine (AZT) or indinavir NC: Culture medium alone Mode of action: Inhibits viral entry. (in vitro) | [51]       |
| Southern Brazil                 | Ethanol         | Influenza A/PR/8/34 (H1N1) Assay: Plaque reduction assay Model: Mice Dose: 10 mg/kg Propolis (EC₅₀ µg/mL):  - AF-05: 62.0 ± 3.4  - AF-06: 60.0 ± 3.7  - AF-07: 59.1 ± 3.9  - AF-08: 22.6 ± 2.0  - AF-17: 19.5 ± 0.8  - AF-18: 45.2 ± 7.8  - AF-19: 34.6 ± 4.0  - AF-20: <10  - AF-M1: 60.3 ± 8.1  - AF-M2: 101.2 ± 2.0  - AF-M3: 111.6 ± 25.1  - AF-G1: 54.3 ± 3.5  - AF-G12: 36.8 ± 16.9 PC: Ribavirin EC₅₀ = 20.2 ± 11.7 µg/mL NC: 1% ethanol solution Mode of action: Not reported. (in vitro and in vivo) | [52]       |
| Cuautitlan Izcalli, State of Mexico | 70% Ethanol     | Pseudo Rabies Virus (PRV) Model: Monolayers of Madin-Darby bovine kidney (MDBK) cells Assay: Plaque assay Tested dose: 0.5 mg /mL PC: Not reported NC: Not infected MDBK cell culture Plaque forming unit: 8.7 Mode of action:  - Possible damage to the viral envelope proteins;  - Affects the penetration of the virus and its replication cycle. (in vitro) | [53]       |

NR: Not reported, NC: normal control, MDBK cell: Madin-Darby bovine kidney cells, PPE: Propolis extract ACF®, AF: propolis extract, PC: positive control.
Moreover, aqueous and ethanolic extracts prepared from propolis showed promising antiviral efficacy against HSV-1 infection of RC-37 cells as evidenced by a plaque formation assay. These therapeutic effects may arise from masking of viral proteins necessary for adsorption or entry into host cells [13]. Aqueous and ethanolic propolis extracts also reduced HSV-2 proliferation with efficacy comparable to acyclovir when applied at different intervals during the viral infection cycle, again likely by masking viral molecules responsible for entrance or adsorption into host cells [46].

Another study conducted on propolis originating from Canada reported that propolis had significant virucidal effects against HVS-1 and -2 and also interfered with HVS-2 entry into Madin-Darby bovine kidney (MDBK) cells [47]. Moreover, French propolis proved effective against different strains of PV-2, VSV, and adenovirus type 2 (Adeno-2), as well as against HSV-1, HSV1-R, and HSV-2, with a 30 µg/mL dose showing the greatest efficacy for inhibiting viral replication [12].

Thus, propolis may inhibit HSV infection through multiple mechanisms, including virucide, inhibition of replication, and blockade of host entry.

Propolis has also demonstrated in vitro antiviral efficacy against human immunodeficiency virus (HIV), the causative pathogen for acquired immune deficiency syndrome (AIDS). According to the World Health Organization (WHO), Africa is the most severely affected region, accounting for nearly two thirds of all current HIV cases worldwide. In fact, nearly 1 in every 25 African adults (4.1%) is currently living with HIV. While there are several antiretroviral drugs available for HIV control, these have serious side effects such as lipodystrophy [54], necessitating the development of safer alternatives. Propolis extracts from different geographic regions of Brazil and China reduced HIV-1 infectivity by 85% in cultures of CD4+ cells and by 98% in cultures of microglial cells both by inhibiting viral entry and by suppressing reverse transcriptase activity [51]. Additionally, eight compounds isolated from Brazilian propolis, including four triterpenoids (melliferone, moronic acid, anwuweizonic acid, and betulonic acid) and four aromatic compounds (4-hydroxy-3-methoxypropiophenone, 4-hydroxy-3-methoxybenzaldehyde, 3-(3,4-dimethoxyphenyl)-2-propenal, and 12-acetoxytremetone), showed anti-HIV-1 activity in H9 lymphocytes (Table 2) [55].

Table 2. List of isolated anti-viral compounds from propolis.

| Origin            | Compound Names | Antiviral Activities/Species                                                                 | References |
|-------------------|----------------|-----------------------------------------------------------------------------------------------|------------|
| Southern Brazil   | Melliferone    | Human immunodeficiency virus (HIV) Model: H9 lymphocytes IC$_{50}$: 0.205 µg/mL PC: AZT IC$_{50}$: 500 µg/mL EC$_{50}$: 0.00289 µg/mL NC: Infected cells with culture medium Mode of action: Inhibits viral replication. (in vitro) | [55]       |
|                   |                |                                                                                               |            |
|                   | Moronic acid   | Human immunodeficiency virus (HIV) Model: H9 lymphocytes IC$_{50}$: 18.6 µg/mL EC$_{50}$ < 0.1 µg/mL | [55]       |
|                   |                | -                                                                                             |            |
|                   |                | PC: AZT                                                                                       |            |
|                   |                | IC$_{50}$: 500 µg/mL EC$_{50}$: 0.00289 µg/mL NC: Infected cells with culture medium Mode of action: Inhibits viral replication. (in vitro) |            |
Table 2. Cont.

| Origin             | Compound Names                        | Antiviral Activities/Species                                                                 | References |
|--------------------|---------------------------------------|---------------------------------------------------------------------------------------------|------------|
|                    | **Anwuweizonic acid**                  | Human immunodeficiency virus (HIV)                                                              | [55]       |
|                    | **Model:** H9 lymphocytes              | Model: H9 lymphocytes  Adamson, J., et al. (2019). Antiviral activities of anwuweizonic acid.    | [55]       |
|                    | **IC50:** 2.14 µg/mL                   | IC50: 2.14 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) |            |
|                    | **PC:** AZT                            | PC: AZT  Adamson, J., et al. (2019). Antiviral activities of anwuweizonic acid.                | [55]       |
|                    | **IC50:** 500 µg/mL                    | IC50: 500 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) |            |
|                    | **Betulonic acid**                     | Human immunodeficiency virus (HIV)                                                              | [55]       |
|                    | **Model:** H9 lymphocytes              | Model: H9 lymphocytes  Adamson, J., et al. (2019). Antiviral activities of Betulonic acid.      | [55]       |
|                    | **IC50:** 1.8 µg/mL                    | IC50: 1.8 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **PC:** AZT                            | PC: AZT  Adamson, J., et al. (2019). Antiviral activities of Betulonic acid.                    | [55]       |
|                    | **IC50:** 500 µg/mL                    | IC50: 500 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **4-Hydroxy-3-methoxypropiophenone**   | Human immunodeficiency virus (HIV)                                                              | [55]       |
|                    | **Model:** H9 lymphocytes              | Model: H9 lymphocytes  Adamson, J., et al. (2019). Antiviral activities of 4-Hydroxy-3-methoxypropiophenone. | [55]       |
|                    | **IC50:** 18.8 µg/mL                   | IC50: 18.8 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **PC:** AZT                            | PC: AZT  Adamson, J., et al. (2019). Antiviral activities of 4-Hydroxy-3-methoxypropiophenone. | [55]       |
|                    | **IC50:** >100 µg/mL                   | IC50: >100 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **4-Hydroxy-3-methoxybenzaldehyde**    | Human immunodeficiency virus (HIV)                                                              | [55]       |
|                    | **Model:** H9 lymphocytes              | Model: H9 lymphocytes  Adamson, J., et al. (2019). Antiviral activities of 4-Hydroxy-3-methoxybenzaldehyde. | [55]       |
|                    | **IC50:** 500 µg/mL                    | IC50: 500 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **PC:** AZT                            | PC: AZT  Adamson, J., et al. (2019). Antiviral activities of 4-Hydroxy-3-methoxybenzaldehyde.  | [55]       |
|                    | **IC50:** >100 µg/mL                   | IC50: >100 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **3-(3,4-Dimethoxyphenyl)-2-propenal** | Human immunodeficiency virus (HIV)                                                              | [55]       |
|                    | **Model:** H9 lymphocytes              | Model: H9 lymphocytes  Adamson, J., et al. (2019). Antiviral activities of 3-(3,4-Dimethoxyphenyl)-2-propenal. | [55]       |
|                    | **IC50:** 18.9 µg/mL                   | IC50: 18.9 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **PC:** AZT                            | PC: AZT  Adamson, J., et al. (2019). Antiviral activities of 3-(3,4-Dimethoxyphenyl)-2-propenal. | [55]       |
|                    | **IC50:** 500 µg/mL                    | IC50: 500 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **12-Acetoxytremetone**                | Human immunodeficiency virus (HIV)                                                              | [55]       |
|                    | **Model:** H9 lymphocytes              | Model: H9 lymphocytes  Adamson, J., et al. (2019). Antiviral activities of 12-Acetoxytremetone. | [55]       |
|                    | **IC50:** 2.07 µg/mL                   | IC50: 2.07 µg/mL  
**EC50:** 0.00289 µg/mL  
**NC:** Infected cells with culture medium  
**Mode of action:** Inhibits viral replication. (in vitro) | [55]       |
|                    | **PC:** AZT                            | PC: AZT  Adamson, J., et al. (2019). Antiviral activities of 12-Acetoxytremetone.              |            |
Table 2. Cont.

| Origin                        | Compound Names | Antiviral Activities/Species                                                                                                                                                                                                 | References |
|-------------------------------|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Uniflora Apicultores Associados (Olimpia, Brazil)/Moravia, Czech Republic | p-Coumaric acid | Human rhinovirus (HRV)-2, HRV-3, and HRV-4 Assay: Ulforhodamine B and real-time reverse transcription PCR Model: HeLa cells HRV-2: IC₅₀ = 371.2 ± 7.74 µM PC: Ribavirin IC₅₀ = 270.1 ± 35.94 µM HRV-3: IC₅₀ = 454.5 ± 3.16 µM PC: Ribavirin IC₅₀ = 307.9 ± 5.53.94 µM HRV-4: IC₅₀ = 604.3 ± 50.93 µM PC: Ribavirin IC₅₀ = 323.9 ± 31.16 µM NC: DMSO Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. (in vitro) | [13,15]    |
| Kaempferol                    |                | Human rhinovirus (HRV)-2, HRV-3, and HRV-4 Assay: Ulforhodamine B and real-time reverse transcription PCR Model: HeLa cells HRV-2: IC₅₀ = 7.3 ± 4.54 µM PC: Ribavirin IC₅₀ = 270.1 ± 35.94 µM HRV-3: IC₅₀ = 11.9 ± 0.42 µM PC: Ribavirin IC₅₀ = 307.9 ± 5.53.94 µM HRV-4: IC₅₀ = 12.9 ± 1.15 µM PC: Ribavirin IC₅₀ = 323.9 ± 31.16 µM NC: DMSO Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. (in vitro) | [13,15]    |
| Origin | Compound Names | Antiviral Activities/Species | References |
|--------|----------------|----------------------------|------------|
|        |                | Human rhinovirus (HRV)-2, HRV-3, and HRV-4 | [13,15] |
|        |                | Assay: Ulforhodamine B and real-time reverse transcription PCR |           |
|        |                | Model: HeLa cells |           |
|        |                | HRV-2 | IC$_{50}$ = 20.0 ± 8.07 µM |          |
|        |                | PC: Ribavirin |          |
|        |                | IC$_{50}$ = 270.1 ± 35.94 µM |          |
|        |                | HRV-3 | IC$_{50}$ = 116.2 ± 0.85 µM |          |
|        |                | PC: Ribavirin |          |
|        |                | IC$_{50}$ = 307.9 ± 5.53.94 µM |          |
|        |                | HRV-4 | IC$_{50}$ = 88.1 ± 28.71 µM |          |
|        |                | PC: Ribavirin |          |
|        |                | IC$_{50}$ = 323.9 ± 31.16 µM |          |
|        |                | NC: DMSO |          |
|        |                | Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. (in vitro) | [13,15] |
| Galangin |                | Herpes simplex virus 1 (HSV-1) | [13,15] |
|        |                | Assay: Plaque reduction |           |
|        |                | Model: RC-37 cells |           |
|        |                | IC$_{50}$ (%): 0.00045; SI: 3.3 |          |
|        |                | PC: Heparin-Na and acyclovir |          |
|        |                | NC: Untreated cells |          |
|        |                | Mode of action: Masks viral compounds which are necessary for adsorption or entry into host cells. (in vitro) |          |
|        |                | Human rhinovirus (HRV)-2, HRV-3, and HRV-4 | [13,15] |
|        |                | Assay: Ulforhodamine B and real-time reverse transcription PCR |           |
|        |                | Model: HeLa cells |           |
|        |                | HRV-2 | IC$_{50}$ = 34.1 ± 10.33 µM |          |
|        |                | PC: Ribavirin |          |
|        |                | IC$_{50}$ = 270.1 ± 35.94 µM |          |
|        |                | HRV-3 | IC$_{50}$ = 15.5 ± 2.29 µM |          |
|        |                | PC: Ribavirin |          |
|        |                | IC$_{50}$ = 307.9 ± 5.53.94 µM |          |
|        |                | HRV-4 | IC$_{50}$ = 18.2 ± 4.14 µM |          |
|        |                | PC: Ribavirin |          |
|        |                | IC$_{50}$ = 323.9 ± 31.16 µM |          |
|        |                | NC: DMSO |          |
|        |                | Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. (in vitro) | [13,15] |
| Origin       | Compound Names | Antiviral Activities/Species                                                                 | References |
|--------------|----------------|---------------------------------------------------------------------------------------------|------------|
| Fisetin      | Human rhinovirus (HRV)-2, HRV-3, and HRV-4 Assay: Ulforhodamine B and real-time reverse transcription PCR Model: HeLa cells HRV-2 IC_{50} = 40.9 ± 15.20 µM PC: Ribavirin IC_{50} = 270.1 ± 35.94 µM HRV-3 IC_{50} = 67.1 ± 3.50 µM PC: Ribavirin IC_{50} = 307.9 ± 5.53.94 µM HRV-4 IC_{50} = 66.4 ± 13.28 µM PC: Ribavirin IC_{50} = 323.9 ± 31.16 µM NC: DMSO Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. (in vitro) | [13,15]    |
| Chrysin      | Human rhinovirus (HRV)-2, HRV-3, and HRV-4 Assay: Ulforhodamine B and real-time reverse transcription PCR Model: HeLa cells HRV-2 IC_{50} = 17.3 ± 9.83 µM PC: Ribavirin IC_{50} = 270.1 ± 35.94 µM HRV-3 IC_{50} = 16.1 ± 4.80 µM PC: Ribavirin IC_{50} = 307.9 ± 5.53.94 µM HRV-4 IC_{50} = 24.4 ± 5.27 µM PC: Ribavirin IC_{50} = 323.9 ± 31.16 µM NC: DMSO Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. (in vitro) | [13,15]    |
|              | Herpes simplex virus 1 (HSV-1) Assay: Plaque reduction Model: RC-37 cells IC_{50} (%): 0.00003; SI: 20 PC: Heparin-Na and acyclovir NC: Untreated cells Mode of action: Masks viral compounds which are necessary for adsorption or entry into host cells. (in vitro) | [13,15]    |
Table 2. Cont.

| Origin | Compound Names | Antiviral Activities/Species | References |
|--------|----------------|-----------------------------|------------|
|        | Luteolin       | Human rhinovirus (HRV)-2, HRV-3, and HRV-4 | [13,15] |
|        |                | Assay: Ulforhodamine B and real-time reverse transcription PCR |          |
|        |                | Model: HeLa cells |          |
|        |                | HRV-2 |          |
|        |                | $\text{IC}_{50} = 37.4 \pm 2.10 \mu M$ |          |
|        |                | PC: Ribavirin |          |
|        |                | $\text{IC}_{50} = 270.1 \pm 35.94 \mu M$ |          |
|        |                | HRV-3 |          |
|        |                | $\text{IC}_{50} = 20.4 \pm 2.63 \mu M$ |          |
|        |                | PC: Ribavirin |          |
|        |                | $\text{IC}_{50} = 307.9 \pm 55.94 \mu M$ |          |
|        |                | HRV-4 |          |
|        |                | $\text{IC}_{50} = 14.7 \pm 7.86 \mu M$ |          |
|        |                | PC: Ribavirin |          |
|        |                | $\text{IC}_{50} = 323.9 \pm 31.16 \mu M$ |          |
|        |                | NC: DMSO |          |
|        |                | Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. |          |
|        |                | (in vitro) |          |
|        | Acacetin       | Human rhinovirus (HRV)-2, HRV-3, and HRV-4 | [13,15] |
|        |                | Assay: Ulforhodamine B and real-time reverse transcription PCR |          |
|        |                | Model: HeLa cells |          |
|        |                | HRV-2 |          |
|        |                | $\text{IC}_{50} = 163.2 \pm 18.97 \mu M$ |          |
|        |                | PC: Ribavirin |          |
|        |                | $\text{IC}_{50} = 270.1 \pm 35.94 \mu M$ |          |
|        |                | HRV-3 |          |
|        |                | $\text{IC}_{50} = 107.6 \pm 18.30 \mu M$ |          |
|        |                | PC: Ribavirin |          |
|        |                | $\text{IC}_{50} = 307.9 \pm 55.94 \mu M$ |          |
|        |                | HRV-4 |          |
|        |                | $\text{IC}_{50} = 102.3 \pm 5.39 \mu M$ |          |
|        |                | PC: Ribavirin |          |
|        |                | $\text{IC}_{50} = 323.9 \pm 31.16 \mu M$ |          |
|        |                | NC: DMSO |          |
|        |                | Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. |          |
|        |                | (in vitro) |          |
| Origin                      | Compound Names                        | Antiviral Activities/Species                                                                 | References |
|-----------------------------|----------------------------------------|---------------------------------------------------------------------------------------------|------------|
|                             |                                        | Human rhinovirus (HRV)-2, HRV-3, and HRV-4                                                  |            |
|                             |                                        | Assay: Ulforhodamine B and real-time reverse transcription PCR                               |            |
|                             |                                        | Model: HeLa cells                                                                           |            |
|                             |                                        | HRV-2                                                                                       |            |
|                             |                                        | IC₅₀  = 67.2 ± 5.89 µM                                                                       |            |
|                             |                                        | PC: Ribavirin                                                                               |            |
|                             |                                        | IC₅₀  = 270.1 ± 35.94 µM                                                                    |            |
|                             |                                        | HRV-3                                                                                       |            |
|                             |                                        | IC₅₀  = 52.2 ± 2.61 µM                                                                       |            |
|                             |                                        | PC: Ribavirin                                                                               | [13,15]   |
|                             |                                        | IC₅₀  = 307.9 ± 55.394 µM                                                                    |            |
|                             |                                        | HRV-4                                                                                       |            |
|                             |                                        | IC₅₀  = 66.1 ± 15.43 µM                                                                      |            |
|                             |                                        | PC: Ribavirin                                                                               |            |
|                             |                                        | IC₅₀  = 323.9 ± 31.16 µM                                                                     |            |
|                             |                                        | NC: DMSO                                                                                    |            |
|                             |                                        | Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. (in vitro) |            |
|                             |                                        | Ferulic acid                                                                                |            |
|                             |                                        | Human rhinovirus (HRV)-2, HRV-3, and HRV-4                                                  |            |
|                             |                                        | Assay: Ulforhodamine B and real-time reverse transcription PCR                               |            |
|                             |                                        | Model: HeLa cells                                                                           |            |
|                             |                                        | HRV-2                                                                                       |            |
|                             |                                        | IC₅₀  = 175.1 ± 29.10 µM                                                                     |            |
|                             |                                        | PC: Ribavirin                                                                               |            |
|                             |                                        | IC₅₀  = 270.1 ± 35.94 µM                                                                    |            |
|                             |                                        | HRV-3                                                                                       |            |
|                             |                                        | IC₅₀  = 248.7 ± 22.30 µM                                                                     |            |
|                             |                                        | PC: Ribavirin                                                                               | [13,15]   |
|                             |                                        | IC₅₀  = 307.9 ± 55.394 µM                                                                    |            |
|                             |                                        | HRV-4                                                                                       |            |
|                             |                                        | IC₅₀  = 232.3 ± 5.05 µM                                                                      |            |
|                             |                                        | PC: Ribavirin                                                                               |            |
|                             |                                        | IC₅₀  = 323.9 ± 31.16 µM                                                                     |            |
|                             |                                        | NC: DMSO                                                                                    |            |
|                             |                                        | Mode of action: Blocks or reduces the entrance of the viruses into the cells to protect the cells from virus destruction and abate virus replication. (in vitro) |            |
| Origin | Compound Names | Antiviral Activities/Species | References |
|--------|----------------|-----------------------------|------------|
| Brazil | Apigenin | Anti-influenza virus Assay: Plaque reduction Model: MDCK A/PR/8/34(H1N1) EC<sub>50</sub> = 15.3 ± 3.0 µg/mL A/Toyama/129/2011(H1N1) EC<sub>50</sub> = 17.8 ± 8.7 µg/mL EC<sub>50</sub> = 8.1 ± 4.7 µg/mL PC: Ribavirin EC<sub>50</sub> = 19.2 ± 7.5µg/mL NC: Distilled water Mode of action: Suppresses the stage of virus replication after adsorption and/or invasion. (in vitro) | [56] |
| Brazil | Arterpillin C | Anti-influenza virus Assay: Plaque reduction Model: MDCK A/PR/8/34(H1N1) EC<sub>50</sub> >40 µg/mL A/Toyama/129/2011(H1N1) EC<sub>50</sub> >40 µg/mL A/Toyama/26/2011(H1N1) EC<sub>50</sub> >40 µg/mL PC: Ribavirin EC<sub>50</sub> = 19.2 ± 7.5µg/mL NC: Distilled water Mode of action: Suppresses the stage of virus replication after adsorption and/or invasion. (in vitro) | [56] |
|        | Kaempferol | Anti-influenza virus Assay: Plaque reduction Model: MDCK A/PR/8/34(H1N1) EC<sub>50</sub> = 38.2 ± 17.1 µg/mL A/Toyama/129/2011(H1N1) EC<sub>50</sub> = 21.7 ± 5.5 µg/mL A/Toyama/26/2011(H1N1) EC<sub>50</sub> = 24.8 ± 4.3 µg/mL PC: Ribavirin EC<sub>50</sub> = 19.2 ± 7.5µg/mL NC: Distilled water Mode of action: Suppresses the stage of virus replication after adsorption and/or invasion. (in vitro) | [56] |
Table 2. Cont.

| Origin | Compound Names                        | Antiviral Activities/Species                      | References |
|--------|---------------------------------------|-------------------------------------------------|------------|
|        | **Caffeic acid**                      | Anti-influenza virus                             | [56]       |
|        | Assay: Plaque reduction               | Model: MDCK                                      |            |
|        | A/PR/8/34(H1N1)                       | EC$_{50}$ > 100 µg/mL                            |            |
|        | A/Toyama/129/2011(H1N1)               | EC$_{50}$ = 49.7 ± 5.0 µg/mL                     |            |
|        | A/Toyama/26/2011(H1N1)                | EC$_{50}$ > 100 µg/mL                            |            |
|        | PC: Ribavirin                         | EC$_{50}$ = 19.2 ± 7.5µg/mL                      |            |
|        | NC: Distilled water                   | Mode of action: Suppresses the stage of virus replication after adsorption and/or invasion. (in vitro) |            |
|        | **Coumaric acid**                     | Anti-influenza virus                             | [56]       |
|        | Assay: Plaque reduction               | Model: MDCK                                      |            |
|        | A/PR/8/34(H1N1)                       | EC$_{50}$ = 31.5 ± 1.3µg/mL                      |            |
|        | A/Toyama/129/2011(H1N1)               | EC$_{50}$ = 16.4 ± 6.6µg/mL                      |            |
|        | A/Toyama/26/2011(H1N1)                | EC$_{50}$ = 27.0 ± 4.9µg/mL                      |            |
|        | PC: Ribavirin                         | EC$_{50}$ = 19.2 ± 7.5µg/mL                      |            |
|        | NC: Distilled water                   | Mode of action: Suppresses the stage of virus replication after adsorption and/or invasion. (in vitro) |            |
|        | **Caffeic acid phenethyl ester (CAPE)** | Herpes simplex viruses (HSV-1 and HSV-2)       | [57]       |
|        | Assay: Microscopic Fourier transform infrared spectroscopy (FTIR) | Model: Mouse embryo fibroblasts (MEF)     |            |
|        | Tested doses: 10 and 50 µM            | PC: NR                                           |            |
|        |                                         | NC: Untreated cells                             |            |

MDCK: Madin-Darby canine kidney cells, NR: Not reported, NC: normal control, PC: positive control.

The ethanolic extract of GH 2002 propolis demonstrated significant antiviral efficacy against varicella zoster virus (VZV), with an IC$_{50}$ of 64 µg/mL as assessed by a plaque reduction assay. This antiviral effect was detected when propolis extract was added at different times during the viral infection cycle. Furthermore, the extract enhanced the inhibitory effect of acyclovir on viral DNA polymerase during VZV replication. These findings again suggest that bioactive components in propolis can both mask viral proteins, thus interfering with entry into host cells, and suppress viral replication [49].

As mentioned, antiviral efficacy depends on the extraction method. A study comparing the antiviral properties of green and red Brazilian propolis extract prepared using two different ultrasonic methods and maceration found that both ultrasonic extracts demonstrated greater activity against bacteriophages MS2 and Av-08 than the maceration extract, while the maceration extract of red propolis was more active than the corresponding green extract for damaging the viral cell membrane and inhibiting polymerase activity [50]. Recently, a Euro-Asian poplar propolis extract treatment for 4 days was found to inhibit H1N1 influenza virus infection of MDCK cells by suppressing both viral growth and neuraminidase (NA) activity (Table 1) [31]. Two bioactive compounds isolated from Brazilian
propolis, kaempferol and p-coumaric acid, were tested for inhibition of HeLa cell infection by three human rhinoviruses, HRV-2, HRV-3, and HRV-4. Kaempferol is the most bioactive compound, with IC$_{50}$ values of 7.3, 11.9, and 12.9 µM toward HRV-2, HRV-3, and HRV-4, respectively, while p-coumaric acid shows the lowest antiviral activity at IC$_{50}$ values of 371.2, 454.5, and 604.3 µM in comparison with ribavirin (positive control). Findings indicate that kaempferol and p-coumaric acid may block or reduce the entry of the viruses into the host cells, in order to preserve the cells from virus replication [15].

Another study on the antiviral effect of Mexican propolis against MDBK cell monolayer infection by pseudo rabies virus (PRV) found that treated cells exhibited an electron-dense layer on the cell membrane that prevented viral entry [53]. Another study of 13 ethanolic extracts from South Brazilian propolis identified four with significant anti-influenza virus activity in vitro and subsequently found antiviral efficacy in vivo after oral administration to infected mice (3 times daily/7 days), with 10 mg/kg showing the greatest therapeutic effect [52].

Other work aimed to compare the effect of three samples, propolis, Baccharis dracunculifolia (extract and essential oil), and some isolated compounds (caffeic and cinnamic acids), on poliovirus type 1 (PV1). Three protocols (pre-, simultaneous, and post-treatments) were used for evaluating the effects on the virus. For propolis, a high inhibition percentage both in simultaneous and post-treatment was recorded. Propolis partially affects both in viral cell entry and cell replication steps in the viral cycle or leads to RNA degradation before the entry of virus to cells [48].

In summary, various bioactive compounds have been identified in Brazilian propolis extract, including antiviral agents effective against different strains of the influenza virus. Three compounds, apigenin, kaempferol, and coumaric acid, were shown to significantly inhibit the infection of MDCK cells by suppressing the post adsorption and invasion stages of viral replication [56]. In general, the antiviral activities of propolis are mediated by flavonoids and other phenolic acids. These active constituents have different modes of action, such as the formation of complexes with viral proteins required for infection (masking), formation of an electron-dense layer on the cell membrane, directly damaging viral envelope proteins, and promoting viral destruction within the cell (Figure 4).

![Figure 4. Anti-viral activity and the possible mode of action of propolis extracts/constituents against different types of viruses.](image-url)
5. Propolis as a Treatment for COVID-19

COVID-19 is a pandemic disease caused by the recently discovered SARS-CoV-2, the seventh known member of the coronavirus family infectious to humans (after SARS coronavirus and Middle East respiratory syndrome (MERS) coronavirus) [58]. The epidemiological burden of COVID-19 is currently a major healthcare challenge throughout the world, as SARS-CoV-2 is readily transmitted from human to human via airborne microdroplets generated during coughing, talking, or sneezing. In addition, SARS-CoV-2 can be transmitted by touching a contaminated surface and then touching the nose, mouth, or eyes [59,60]. While many drugs have been screened for efficacy against SARS-CoV-2 infection, no antiviral agent has yet proven broadly efficacious [61]. However, several natural product derivatives have shown promise as effective non-toxic antiviral agents [62]. Potential therapeutic agents may include honeybee products in addition to propolis, such as honey, royal jelly, bee venom, wax, bee pollen, and bee bread, as all have demonstrated antimicrobial, antifungal, anti-inflammatory, and (or) antiviral properties under certain conditions [63]. Propolis has also shown promising broad spectrum antiviral effects in vitro and in vivo against influenza virus, human respiratory syncytial and coronaviruses, rotavirus, and human rhinovirus, among others, suggesting potential efficacy against coronaviruses [16,64,65].

The potential efficacy of five propolis-derived flavonoids was recently evaluated in vitro on different DNA and RNA viruses, including coronaviruses, using the viral plaque reduction technique. Acacetin and galangin had no effect on either the infectivity or replication of any of the viruses tested, but chrysin and kaempferol were highly effective in inhibiting replication, and quercetin was active against infectivity and replication at higher concentrations [17]. Refaat et al. investigated the in vitro effects of crude Egyptian propolis extract and a propolis liposome preparation on SARS-CoV-2 3CL-like protease, S1 spike protein, and viral replication by RT-PCR. Liposomes inhibited SARS-CoV-2 3CL protease activity with an IC_{50} of 1.183 ± 0.06 µg/mL, while the crude propolis extract inhibited 3CL protease activity with an IC_{50} of 2.452 ± 0.11 µg/mL, values comparable to Remdesivir [18]. Sulawesi propolis and its components glyasperin A, broussoflavonol F, and sulabiroins A also inhibited SARS-CoV-2 3C-like protease activity and interacted with the protease catalytic sites His^{41} and Cys^{145}, with docking scores of −7.8, −7.8, and −7.6 kcal/mol, respectively [19]. Similarly, Hashem et al. evaluated the in silico inhibitory activity of six selected compounds present in propolis, 3-phenyllactic acid, CAPE, lumichrome, galangin, chrysin, and caffeic acid, against SARS-CoV-2 3CL^{pro} and found that all six showed good docking scores, with the most potent being CAPE (−6.383 kcal/mol), chrysin (−6.097), and galangin (−6.295) [20].

Other studies have found that propolis is able to inhibit the activity of P21 (RAC1) Activated Kinase 1 (PAK1), a major “pathogenic” kinase in several diseases/disorders, including inflammation, cancer, malaria, and pandemic viral infections such as HIV, influenza, and COVID-19 [66]. Additionally, CAPE was found to bind and inhibit SARS-CoV-2 transmembrane protease serine 2 to a degree comparable with Camostat mesylate as evidenced by molecular docking and molecular dynamics (MD) simulations [34]. Moreover, quercetin alone and in conjunction with vitamin C was predicted to suppress SARS-CoV-2 infection by binding to 3C-like protease (3CL^{pro}) [67,68]. A pilot randomized clinical study assessed the potential efficacy of Brazilian green propolis (400 or 800 mg/day orally or via nasoenteral tube) against SARS-CoV-2 (NCT04480593). In addition, it supported the idea that propolis may be an effective agent to combat coronavirus-induced fibrosis in the lungs [65].

6. Immunomodulatory Activity

Although propolis has been mentioned as an immunomodulatory agent for centuries, little was known about its action until the 1990s. In the last decade, however, new and interesting articles have been published, contributing greatly to this field of research [69]. The immunomodulatory activity of propolis standard extract in allergic asthma was investigated by Piñeros [70] (Figure 5). The chronic inflammatory disease is mediated by
Th2 inflammation and an increased number of CD4+ T cells, which produces an excess of cytokines including interleukin-4 (IL-4), IL-5, and IL-13. It is also characterized by eosinophilic infiltration and mast cell activation [71,72]. Ovalbumin (OVA)-induced allergy model animals were treated daily by gavage with 150 mg/Kg of propolis for 17 days. Propolis treatment reduced pulmonary Th2 inflammation and decreased eosinophil infiltration as well as IL-5 levels in Bronchoalveolar lavage fluid (BALF). Propolis also induced the differentiation and frequency of myeloid-derived suppressor cells (MDSC) and CD4+ Foxp3+ regulatory T cells [70]. These findings are consistent with a study by Sy et al., reporting that low and high doses of propolis aqueous extract (65 mg/kg and 325 mg/kg body weight) decreased BALF IL-5 concentration, IL-6 and IL-10 production by splenocytes, and the serum levels of immunoglobulin E (IgE) and immunoglobulin G (IgG) antibodies [73].

![Figure 5](image-url)

**Figure 5.** Representative scheme demonstrates some of the possible immune-mediated mechanisms of propolis in (A) Allergic asthma: Asthma is mediated by Th2 inflammation in which CD4 T-cells produce an excess of IL-4, IL-5, and IL13 cytokines. IL-4 triggers the production of IgG antibodies by B-cells, whereas IL-5 activates and promotes the infiltration of eosinophils to airways inducing bronchial inflammation, and IL-13 mainly participates in mucus hypersecretion [74]. Propolis inhibits IL-5 production, mucus hypersecretion, eosinophil infiltration, and IgE produced by B cells. (B) Antimicrobial: Propolis upregulates the production of Toll-like receptors (TLRs) which have a vital role in the recognition of pathogen-associated molecular patterns (PAMPs), conserved molecules expressed by microbes. TLRs signal macrophages and dendritic cells triggering the production of inflammatory cytokines. (C) Leishmaniasis: Propolis activates macrophages and dendritic cells and induces the differentiation and frequency of myeloid-derived suppressor cells (MDSC) and CD4+ Foxp3+ regulatory T cells. CAPE was found to hinder T cell-dependent production of chemokines and cytokines as well as of antibodies induced by in-vivo administration of ovalbumin (OVA)-induced allergies [73].

The immunosuppressive properties of propolis have also been investigated in models of rheumatoid arthritis (RA). Dietary administration of propolis ethanolic extract (6.7 and 20 mg/g) was found to reduce the severity of this autoimmune disease in vivo by inhibiting production of IL-17 [75], a pro-inflammatory cytokine produced by Th cells (Th17 cells) strongly implicated in RA pathogenesis (e.g., joint inflammation and destruction of bone and cartilage) [76]. As such, targeting Th17 cells and targeting the IL-17 signaling pathway are potential strategies for RA treatment, and indeed, such treatments are currently under investigation [77]. Okamoto et al. reported that Brazilian propolis suppressed Th17 cell activity in vitro at 12.48 µg/mL by inhibiting the IL-6-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3), a key transcription factor driving Th17 cell differentiation. In addition, Th17 cell differentiation induced by transforming growth factor-β (TGF-β) plus IL-16 was downregulated by propolis in RA model animals, while propolis induced no detectable cellular toxicity at concentrations up to...
96 μg/mL [78]. The propolis-derived compound CAPE has also been reported to suppress autoimmune uveoretinitis. CAPE was found to hinder T cell-dependent production of chemokines and cytokines as well as of antibodies induced by interphotoreceptor retinoid binding protein (IRBP). Treatment with 200 μL CAPE also reduced serum concentrations of TNF-α, IL-6, interferon-γ (IFN-γ), and TNF-α in the retina and inhibited the transcriptional activity of nuclear factor-kappa B (NF-κB) and phospho-IκBα. Hence, it was concluded that the immunosuppressive activity of CAPE in uveitis is mediated by suppression of the pro-inflammatory NF-κB–cytokine pathway [79].

Propolis extracts and derivatives may also augment microbe-induced immune responses by modulating Toll-like receptor (TLR) signaling. Toll-like receptors recognize pathogen-associated molecular patterns (PAMPs), conserved molecules expressed by many microorganisms [80]. Toll-like receptor 2 (TLR2), for instance, recognizes lipoteichoic acid on Gram-positive bacteria and fungi, while TLR-4 recognizes lipopolysaccharide on Gram-negative bacteria [81]. Toll-like receptors are mainly expressed by antigen-presenting cells (APCs), including monocytes, macrophages, B cells, and dendritic cells (DCs) [82]. These cells also express human leukocyte antigen-DR isotype (HLA-DR) and cluster of differentiation 80 (CD80) molecules that present peptides to T cells, resulting in T cell activation. Additionally, TLR signal transduction may activate transcription factors controlling the expression of genes encoding chemokines, cytokines, and antimicrobial peptides [83].

Treatment of BALB/c mice with 200 mg/kg of 30% propolis ethanolic extract for three consecutive days increased expression of TLR-2 and TLR-4 by peritoneal macrophages and spleen cells and elevated the production of IL-1β and IL-6 [84]. In another study, propolis treatment of mice prevented the inhibition of TLR-2 and TLR-4 induced by 14 days of restraint stress. Additionally, real-time polymerase chain reaction (RT-PCR) revealed a significant increase in TLR gene expression in mice receiving propolis treatment without stress [81]. Propolis treatment (10, 20, and 40 μg/mL) also increased the expression of TLR-4 and CD8 by human DCs through a mechanism involving has-miR-155, resulting in enhanced bactericidal activity against Streptococcus mutans, and promoted the production of NF-kB, TNF-α, IL-6, and IL-10 [85]. Conversely, cinnamic acid (5–100 μg/mL) downregulated the expression levels of TLR-2, HLA-DR, and CD80 by human monocytes, although this treatment upregulated TLR-4. High concentrations of cinnamic acid also inhibited expression of TNF-α and IL-10. As TNF-α is known to activate monocytes and macrophages, while IL-10 inhibits these cells, Conti et al. concluded that the increase in fungicidal activity could be due to mechanisms involving other cytokines [83]. Following a similar protocol, Búfalo et al. found that caffeic acid inhibited the expression of TLR-2 and HLA-DR, while CD80 and TLR-4 were not affected. The fungicidal activity of monocytes increased, however, despite the decrease in TNF-α and IL-10 [86].

The in vivo antileishmanial effect of Brazilian propolis was reported for the first time by Pontin et al., that is, an administration of the hydroalcoholic extract at a dose of 1.5 mg/kg/day reduced the lesion diameter in Leishmania braziliensis infected albino mice by 90% after 90 days of treatment. Pontin et al. pointed out that the reduction could be a result of the activation of macrophages and their phagocytic capacity [87]. Consistent with this explanation, da Silva et al. found that 5 and 10 μg/mL propolis activated macrophage phagocytic activity and in turn increased parasite interiorization. This upregulation of macrophage activity was attributed to increased TNF-α and reduced IL-12 signaling. Morphological changes in promastigote forms of Leishmania were also observed by scanning electron microscopy upon treatment [88]. Additionally, propolis was found to regulate the expression of CCL5 and IFN-γ, factors involved in the development of Th1 cells in leishmaniasis patients. Leishmaniasis is usually associated with the development of a strong Th1 response that impairs the wound healing process [89]. In another study by dos Santos Thomazelli et al., the hydroalcoholic extract showed an immunomodulatory effect on both healthy donors and American tegumentar leishmaniasis patients’ human-derived peripheral blood mononuclear cells (PBMC) in leishmaniasis models. This impact was
explained by the increase in IL-4 and IL-17 and a decrease in IL-10 in a dose-dependent manner. On the other hand, nitric oxide (NO) levels remained constant [90].

Numerous studies have also suggested that propolis extracts can suppress tumor growth or promote immune-mediated tumor destruction. Benkovic et al. examined the possible synergistic effect of a water-soluble derivative of propolis (WSDP) and ethanolic extract of propolis (EEP) with the anticancer drug irinotecan in Swiss albino mice inoculated with Ehrlich ascites tumor (EAT) cells. Intraperitoneal injection of WSDP and EEP at 100 mg/kg for three days prior to 50 mg/kg irinotecan injection enhanced the antitumor efficacy and reduced the non-target cytotoxicity of irinotecan compared to irinotecan alone or the combination of irinotecan with the phenolic compounds quercetin and naringin [91]. Further investigation revealed that the decrease in irinotecan-induced non-target cytotoxicity was due to the immunomodulatory properties of propolis. Pretreatment with WSDP+EEP activated macrophages and increased the number of neutrophils in the peritoneal cavity [92]. Oršolić et al. [93] also reported that WSDP at 50 or 150 mg/kg suppressed metastasis and tumor development in mice transplanted with mammary carcinoma cells. This antimetastatic effect was associated with macrophage activation and ensuing nonspecific tumor resistance. Additionally, high levels of lymphocyte activating factor (LAF) produced by these activated macrophages increased tumor cell killing efficiency. Furthermore, WSDP significantly increased the expression of CD4+ and CD8+ by splenocytes [93]. It was concluded that the antitumor activity of WSDP is likely due to the synergistic effects of constituent polyphenolic compounds such as caffeic acid, quercetin, chrysin, and naringenin, and it was further proposed that these compounds interfere with tumor growth by enhancing apoptosis, macrophage activation, and production of pro-inflammatory cytokines such as IL-1, IL-6, IL-8, TNF-α, and NO, some of which can directly damage tumor cells, whereas others act indirectly by enhancing the activities of natural killer (NK) cells and cytotoxic T lymphocytes. Furthermore, these factors stimulate the production of complement factor C3 production and C-reactive protein, which participate in the opsonization of tumor cells [94–96].

Propolis was also shown to reduce the severity of Aujeszky disease when used as a vaccine adjuvant. Mice treated with 5 mg propolis extract, aluminum hydroxide Al(OH)₃, and inactivated Suid herpesvirus type 1 (SuHV-1) demonstrated significantly higher neutralizing antibody titers than mice receiving vaccine without propolis, indicating that the adjuvant properties of propolis are associated with enhanced humoral and cellular immunity related to increased IFN-γ mRNA production. Moreover, expression of mRNA IFN-γ was even higher when propolis was conjugated with antigen [97]. Although numerous preclinical studies have shown the potential efficacy of propolis against immunological diseases, standardized quality controls and well-designed clinical trials are needed before propolis or its components can be adopted as therapeutics (Table 3) [98].

**Table 3.** The immunomodulatory effect of propolis.

| Place of Propolis Collection | Type of Extract | Immunomodulatory Effect | References |
|-----------------------------|-----------------|-------------------------|------------|
| Northeast of Algeria | 85% Ethanol | Celiac Disease (immune-mediated enteropathy)  
Assay: Griess method, ELIZA, and immunofluorescence assay  
Model: Peripheral blood mononuclear cells (PBMCs)  
Tested doses: 1, 50, and 100 µg/mL  
Mode of action:  
- Increases NO and IFN-γ levels, and increases IL-10 levels;  
- Decreases iNOS expression and downregulates the activity of NFkB and pSTAT-3 transcription factors. (ex vivo) | [99] |
### Table 3. Cont.

| Place of Propolis Collection | Type of Extract | Immunomodulatory Effect | References |
|------------------------------|-----------------|-------------------------|------------|
| Brazil                       | 70% Ethanol     | Antifungal immunity     | [82]       |
|                              |                 | Assay: Flow-cytometry and ELISA |          |
|                              |                 | Model: Human monocytes |            |
|                              |                 | Tested doses: 5, 10, 25, 50, and 100 µg/mL |            |
|                              |                 | Mode of action:         |            |
|                              |                 | - Upregulates TLR-4 and CD80; |            |
|                              |                 | - Increases the fungicidal activity of monocytes. | (in vitro) |
| Brazil                       | Ethanol         | Antileishmaniasis       | [88]       |
|                              |                 | Assay: Examination by SEM spectroscopy, |          |
|                              |                 | Phagocytic Assay, ELISA |            |
|                              |                 | Model: Human urine (in vitro), macrophages | (in vivo) |
|                              |                 | Tested doses: 5, 10, 25, 50, and 100 µg/mL (in vitro) |            |
|                              |                 | Mode of action:         |            |
|                              |                 | - Increases TNF-α and decreases IL-12 production; |            |
|                              |                 | - Increases parasite interiorization by macrophages. | (in vitro, in vivo) |
| Brazil                       | Propolis standard extract (dry extract) | Allergic asthma | [70]       |
|                              |                 | Assay: Flow cytometry, real time-PCR, and ELIZA |          |
|                              |                 | Model: Bronchoalveolar lavage fluid (BALF) of allergic mice |          |
|                              |                 | Tested doses: 150 mg/Kg every day for 17 days |            |
|                              |                 | Mode of action:         |            |
|                              |                 | - Decreases pulmonary inflammation and mucus production as well as eosinophils and IL-5; |            |
|                              |                 | - Enhances differentiation and frequency of lung MDSC and CD4+ Foxp3+ regulatory T cells. | (in vitro, in vivo) |
| Northern Morocco              | Ethanol         | Immunomodulation        | [100]      |
|                              |                 | Assay: Cytotoxic and cytostatic assays, MTT assay, and ELISA |          |
|                              |                 | Model: MCF-7, HCT, THP-1, and PBMNCs cell lines IC50: 479.22, 108.88, and 50.54 µg/mL |          |
|                              |                 | Tested doses: 125 and 250 µg/mL |            |
|                              |                 | Mode of action:         |            |
|                              |                 | - Suppresses the TNF-α and IL-6 production in LPS-stimulated PBMNCs; |            |
|                              |                 | - Increases IL-10 in a dose-dependent manner. | (in vitro) |
| Brazil                       | 0.1% Ethanol    | Leishmaniasis           | [90]       |
|                              |                 | Assay: Cytometric bead array assay, indirect immunofluorescence assay |          |
|                              |                 | Model: PBMNCs           |            |
|                              |                 | Tested doses: 5 and 25 µg/mL |            |
|                              |                 | Mode of action:         |            |
|                              |                 | Increases IL-4 and IL-17 and decreases IL-10. | (in vitro) |
| Place of Propolis Collection | Type of Extract | Immunomodulatory Effect | References |
|-----------------------------|----------------|------------------------|------------|
| Iran                        | 30% Ethanol    | Immunomodulation on tumor-bearing mice with disseminated candidiasis Assay: ELISA Model: Mouse mammary tumor Tested doses: 100 mg/kg Mode of action: Decreases IL-4 and IL-10 levels and increases TNF-α and IFN-γ levels. (in vitro) | [101] |
| Iran                        | Ethanol        | Lipopolysaccharide-induced inflammation Assay: MTT assay, the Griess method, flow cytometry real-time PCR, and MTT assays Model: Murine macrophage (RAW 264.7) IC₅₀: 15 ± 3.2 µg/mL Tested doses: 15, 1.5, 0.15 µg/mL Mode of action: Inhibits NO and ROS production and then decreases COX-2, IL-1β, and IL-6 gene expression. (in vitro) | [102] |
| Brazil                      | 70% Ethanol    | Immunomodulation Assay: MTT assay, ELISA, RT-qPCR, flow cytometry Model: Human DCs Tested doses: (5, 10, 20 and 40 µg/mL) Mode of action: Activates human DCs; induces the NF-kB signaling pathway and TNF-α, IL-6, and IL-10 production; inhibits the expression of hsa-miR-148a and hsa-miR-148b; and increases of miR-155 expression. (in vitro) | [85] |
| Brazil                      | 70% Ethanol    | Immunomodulation Assay: ELISA, real-time PCR Model: Peritoneal macrophages and spleen cells in BALB/c mice Tested doses: 200 mg/kg, 0.1 mL for 3 consecutive days by gavage Mode of action: - Increases IL-1β production and TLR-2 and TLR-4 expression in peritoneal macrophages and spleen cells; - IL-6 production was also upregulated in the spleen cells. (In vivo) | [84] |
| Brazil                      | Cuba Mexico    | Immunomodulation Assay: MTT assay and ELISA Model: PBMNCS Tested doses: 0.2, 1.0, 2.0, 10.0, and 20.0 µg/mL Mode of action: Stimulates both TNF-α and IL-10 production by monocytes. (in vitro) | [103] |
| Place of Propolis Collection | Type of Extract | Immunomodulatory Effect | References |
|-----------------------------|-----------------|-------------------------|------------|
| NR                          | Aqueous         | Immunomodulatory activity in Zymosan-induced paw oedema | [104] |
|                             |                 | Assay: AP complement assay, microtiter assay | |
|                             |                 | Model: Zymosan-induced paw oedema in mice strain ICR | |
|                             |                 | Tested doses: 150 mg/kg | |
|                             |                 | Mode of action: Inhibits the formation of edema by activation of alternative pathway (AP) complement. | (in vivo) |
| Turkey                      | 96% Ethanol     | Immunomodulation | [105] |
|                             |                 | Assay: MTT, high-pressure liquid chromatography, ELISA | |
|                             |                 | Model: PBMCNCS | |
|                             |                 | Tested doses: NR | |
|                             |                 | Mode of action: Dose-dependent downregulation by induction of neopterin production and tryptophan degradation and inhibition of TNF-α and IFN-γ levels. | (in vitro) |
| Brazil                      | 70% Ethanol     | Immunomodulation | [106] |
|                             |                 | Assay: Cytotoxicity assay, ELISA | |
|                             |                 | Model: Peritoneal macrophages of BALB/c mice | |
|                             |                 | Tested doses: 5, 50, and 100 mg/well | |
|                             |                 | Mode of action: | |
|                             |                 | - Increases IL-1β; | |
|                             |                 | - Inhibits IL-10 and IL-6 production. | (in vitro) |
| Brazil                      | 70% Ethanol     | Immunomodulation | [81] |
|                             |                 | Assay: Radioimmunoassay, quantitative real time PCR, ELISA | |
|                             |                 | Model: C57BL/6 mice | |
|                             |                 | Tested doses: 200 mg/kg | |
|                             |                 | Mode of action: Increases the gene expression of TLR-2 and TLR-4. | (in vivo) |
| Brazil Lyophilized samples | 70% Ethanol     | Ant-inflammatory | [107] |
|                             |                 | Assay: 2,2-Diphenyl-1-picrylhydrazyl free radical (DPPH) scavenging method Griess reaction, MTT assay, ELISA | |
|                             |                 | Model: Raw 264.7 cells and a mouse leukemic monocyte macrophage cell line (ATCC TIB-71) | |
|                             |                 | Tested doses: 5, 10, 25, 50, and 100 µg/mL | |
|                             |                 | Mode of action: Inhibits NO production in macrophages and suppresses p38 MAPK, JNK1/2 pathways. | (in vitro) |
| Brazil                      | Lyophilized     | Immunomodulation | [108] |
|                             | samples         | Assay: Cotton Pellet Granuloma, ELISA, histopathology analysis | |
|                             |                 | Model: Swiss and Balb/c mice | |
|                             |                 | Tested doses: 5 mg/kg | |
|                             |                 | Mode of action: Decreases the concentration of TNF-α and IL-6 and increases TGF-β and IL-10. | (in vivo) |
| Place of Propolis Collection | Type of Extract | Immunomodulatory Effect | References |
|------------------------------|----------------|------------------------|------------|
| Brazil 70% Ethanol           | Antifungal immunity | Assay: MTT, Flow Cytometry, ELISA
Model: PBMNCS
Tested doses: 5, 10, 25, 50, and 100 µg/mL
Mode of action:
- Downregulates the expression of TLR-2, HLA-DR, and CD80 and upregulates the expression of TLR-4;
- High concentrations inhibited the production of TNF-α and IL-10. |
| [83]                         |

| Brazil 70% Ethanol           | Immunomodulatory in acutely stressed mice | Assay: ELISA
Model: BALB/c male mice
Tested doses: 200 mg/kg/day, 0.1 mL
Mode of action: Increases IL-4 production in stressed mice. |
| [109]                        |

| Brazil 70% Ethanol           | Immunomodulatory activity melanoma-bearing mice submitted to stress | Assay: ELISA, Real-time PCR
Model: C57BL/6 male mice
Tested doses: 200 mg/kg
Mode of action: Upregulates the expression of TLR-2, IL-10, and IFN-γ. |
| [110]                        |

| Brazil 70% Ethanol           | Immunomodulation | Assay: Real Time PCR, ELISA
Model: BALB/c male mice
Tested doses: 200 mg/kg/day, 0.1 mL
Mode of action: Immunorestorative role in TLR-4 expression. |
| [111]                        |

| Brazilian propolis provided by Yamada Apiculture Center, Japan 70% Ethanol | Rheumatoid arthritis | Assay: RT-PCR, ELISA, flow cytometry
Model: DBA/1J mice
Tested doses: (6.7 mg/g diet) and high dose (20 mg/g diet) propolis
Mode of action: Inhibits production of IL-17 and the differentiation of Th17 cells. |
| [75]                         |

| Brazil 70% Ethanol           | Fungicidal activity | Assay: Flow cytometry, ELISA
Model: PBMNCS
Tested doses: 5, 10, 25, 50, and 100 µg/mL
Mode of action: Downregulates the expression of TLR-2 and HLA-DR, inhibits TNF-α and IL-10 production, and increases fungicidal activity. |
| [86]                         |
Table 3. Cont.

| Place of Propolis Collection | Type of Extract | Immunomodulatory Effect | References |
|------------------------------|-----------------|-------------------------|------------|
| Brazilian propolis provided by Yamada Apiculture Center, Japan | Ethanol | Rheumatoid arthritis  
Assay: Cytotoxicity assays, Flowcytometry, Western blot analysis  
Model: splenocytes from Balb/c mice  
Tested doses: 12, 48 µg/mL  
Mode of action:  
- Inhibits IL-6 plus TGF-β-induced Th17 differentiation;  
- Suppresses IL-6-induced phosphorylation of STAT3.  
(in vitro) | [78] |
| Beekeeping Section, UNESP | 70% Ethanol | Immunomodulation  
Assay: Real-time PCR, ELISA  
Model: Male BALB/c mice  
Tested doses: 200 mg/kg, 0.1 mL  
Mode of action: Inhibits the production of IFN-γ.  
(in vivo) | [112] |
| Bulgaria | Ethanol | Prophylactic activity against Gram-negative bacteria  
Assay: Negative Limulus amoebocyte lysate assay  
Model: Strain ICR mice  
Tested doses: 150 mg g-1  
Mode of action: Production of C1q Macrophages, and change in the alternative complement pathway hemolysis.  
(in vivo) | [113] |
| Croatia | - Water-soluble derivative of propolis (WSDP) was prepared by freeze-drying ethanolic propolis extract  
- Ethanol propolis extract was prepared by 80% (V/V) ethanol | Immunomodulatory effect against irinotecan-induced toxicity and genotoxicity  
Assay: Hematological analysis, peripheral blood micronucleus (MN) assay  
Model: Male albino mice of the Swiss strains  
Tested doses: 100 mg/kg  
Mode of action: Inhibits the growth of Ehrlich ascites tumors (EAT) by activation of macrophages and neutrophils, which inhibits Irinotecan induced toxicity.  
(in vivo) | [92] |
| Croatia | WSDP | Antimetastatic effect against lung cancer  
Assay: Flow cytometry, colorimetric Griess reaction  
Model: CBA inbred mice  
Tested doses: 50 or 150 mg/kg  
Mode of action: Suppression of metastasis by activation of macrophages and production of TNF-α, H2O2, and nitric oxide NO.  
(in vivo) | [114] |
| Brazil | 70% Ethanol | Immunomodulation  
Assay: ELISA, spleen cells proliferation assay  
Model: Spleen cells of BALB/c male  
Tested doses: 2.5, 5, and 10 mg/kg, for 3 days  
Mode of action: Decreases splenocyte proliferation and stimulates IFN-γ production.  
(in vitro) | [115] |
| Place of Propolis Collection | Type of Extract | Immunomodulatory Effect | References |
|-----------------------------|----------------|-------------------------|------------|
| Brazil, Croatia             | WSDP           | Antimetastatic effect against lung cancer Assay: Flow cytometry, Plaque-forming cells assay, hematological analysis Model: Male and female CBA inbred mice Tested doses: 50 or 150 mg/kg and 50 mg/mL Mode of action: Suppression of metastasis and increased level of LAF produced macrophages. (in vitro, in vivo) | [93] |
| NR                          | WSDP           | Transplantable mammary carcinoma Assay: Colorimetric Griess reaction, hematological analysis Model: Male and female CBA inbred mice Tested doses: 50 or 150 µg/kg Mode of action: Inhibits tumor by macrophages activation, induces NO production, increases, the response of splenocytes to monoclonal antibodies, and inhibits \(^{3}\)H]Tdr incorporation into HeLa cells. (in vitro) | [116] |
| Brazil                      | 70% Ethanol    | Antileishmanial activity Assay: MTT assay, real-time PCR Model: PBMNCs Tested doses: 5, 10, 25 µg/mL Mode of action: Reduces the expression of CCL5 and IFN-γ. (in vitro) | [89] |
| Brazil                      | Hydroalcoholic extract | Antileishmanial activity Assay: Neutral red method Model: Male Balb/C albino mice (lineage of Mus musculus), Tested doses: 1.5 mg/kg/day Mode of action: NR (in vitro) | [87] |
| Brazil                      | 70% Ethanol    | Immunomodulatory activity in chronically stressed mice Assay: Griess Reaction, histopathological analysis Model: Male BALB/c mice Tested doses: 200 mg/kg Mode of action: Increases production of H₂O₂ and inhibits NO. (in vivo) | [117] |
| Bulgaria                    | WSDP           | Immunomodulatory activity Assay: Popliteal lymph node assay Model: Macrophage Tested doses: 50 and 150 mg/kg Mode of action: Activation of macrophages, which induces the production of IL-1. (in vitro) | [118] |
| Croatia, Brazil             | WSDP           | Immunomodulatory activity against Ehrlich ascites tumor Assay: Differential cell counts Model: Male albino mice of the Swiss strain Tested doses: 50 mg/kg Mode of action: Increases macrophage spreading activity. (in vivo) | [94] |
Table 3. Cont.

| Place of Propolis Collection | Type of Extract | Immunomodulatory Effect | References |
|-----------------------------|-----------------|-------------------------|------------|
| Croatia                     | WSDP            | Ehrlich ascites tumor    | (in vivo)  |
|                             |                 | Assay: Macrophage spreading assay, colorimetric Griess reaction, plaque-forming cells (PFC) assay, biuret method |
|                             |                 | Model: Male and female CBA and Swiss albino inbred mice |
|                             |                 | Tested doses: 50 mg/kg |
|                             |                 | Mode of action: Increases cytotoxic T-cell, NK, and B cells activity. |
| [95]                        |                 |                         |            |
| Croatia Brazil              | WSDP            | Immunomodulatory activity in lung metastases | (in vivo)  |
|                             |                 | Assay: Flow cytometry    |
|                             |                 | Model: Male and female CBA inbred mice |
|                             |                 | Tested doses: 50 or 150 mg/kg |
|                             |                 | Mode of action: Reduces metastases, delays tumor formation, and increases survival of treated animals. |
| [119]                       |                 |                         |            |
| Croatia Brazil              | WSDP            | Immunomodulatory activity in metastasis mammary carcinoma | (in vivo)  |
|                             |                 | Assay: Griess method, plaque-forming cells assay, flow cytometry |
|                             |                 | Model: Human cervical carcinoma cells (HeLa) |
|                             |                 | Tested doses: 50 and 150 mg/kg |
|                             |                 | Mode of action: Inhibits metastasis of mammary carcinoma, induces apoptosis, activates macrophages, increases CD4+ and CD8+ T cells, and induces the production of NO. |
| [96]                        |                 |                         |            |
| Bulgaria                    | 70% Ethanol     | (Parasitemia) Trypanosoma cruzi | (in vivo)  |
|                             |                 | Assay: Flow cytometry    |
|                             |                 | Model: Swiss mice |
|                             |                 | Tested doses: 25 to 100 mg/kg |
|                             |                 | Mode of action: Preferential expansion of CD8+, inhibits CD4+ CD69+ and CD8+ CD69+ in CD4+ CD44+ and CD8+ CD44+, and decreases CD8+ CD62L in Trypanosoma cruzi-infected mice. |
| [120]                       |                 |                         |            |

ELISA: Enzyme-linked immunosorbent assay, PBMNCs: Peripheral blood mononuclear cells, NR: not reported, STAT3: signal transducer and activator of transcription 3, IL-10: Interleukin 10, IL-6: Interleukin 6, IL-1β: Interleukin IL-1β, TLR-4: Toll-like receptor-4, TLR-2: Toll-like receptor-2, TNF-α: Tumor necrosis factor alpha, MTT assay: (3-[4,5-Dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay, TGF-β: Transforming growth factor-β, HLA-DR: Human leukocyte antigen—DR isotype.

7. Clinical Applications of Propolis as an Antiviral and Immunomodulatory Agents

According to a recent review, six separate trials have found that propolis possesses better antiviral efficacy against herpes viruses than acyclovir (summarized in Table 4) [121]. A randomized, single-blind study involving 90 men and women diagnosed with HSV type 2 reported that a significantly greater number of patients treated with propolis ointment containing natural flavonoids (24 of 30) achieved symptom amelioration compared to patients receiving acyclovir (14 of 30) or vehicle (12 of 30) as determined by gynecologists, dermatovenerologists, or urologists, with no difference in medication-related adverse effects (Table 4) [122].
| Activity/Disease | Therapeutic Effect | Preclinical/Clinical Trials/Number of Participants | Dose/Administration Route | References |
|------------------|-------------------|--------------------------------------------------|--------------------------|------------|
| Anti-viral/genital herpes (HSV-2) | Heal genital herpetic lesions and reduce local symptoms | Randomized controlled trials/90 p | Four times daily for 10 days/topical | [122] |
| Anti-viral/HSV-1 | Treat herpetic skin lesions | NR | Propolis 3%/topical | [121] |
| Anti-viral/Herpes zoster | Heal skin lesion and reduce pain | Clinical trial/60 p | Propolis lotion (3 times/day topical) + Acyclovir (400 or 800 mg oral) for 28 days | [123,124] |
| Anti-viral/Herpes labialis | Reduce pain, short healing time with painless incrustation | Randomized, double-blind trial/150 p | Propolis (0.1%, 0.5% and 1%)/topical | [125] |
| Anti-viral/Herpes labialis | Reduce pain, burning, itching, tension, and swelling | Randomized, single-blind trial/379 p | Propolis 0.5%/5 times per 5 days/topical | [126] |
| Anti-viral/Herpes labialis | Treat episodes of herpes labialis | Randomized, controlled double-blind study/397 p | Propolis 0.5%/0.2 g) 5 times per 5 days/topical | [127] |
| Anti-viral/dengue hemorrhagic fever virus | Reduce TNF-α levels and improve platelet counts | Randomized, double-blind, placebo-controlled trial/63 p | Propolis 200 mg three times a day for 7 days/oral | [3] |

Similarly, a propolis lotion produced significantly greater healing rates than a propolis-free lotion (placebo control) following Herpes zoster virus infection ($p < 0.001$ for pain reduction at all visits, reduced new vesicles on day 7 of treatment, and greater global efficacy on the last (28th) day of treatment) with excellent skin tolerability and no allergic reactions, skin irritations, or other adverse events [123]. Holcová et al. utilized three different concentrations (0.1%, 0.5%, and 1%) of propolis special extract GH 2002 in a lip balm through a double-blind, randomized dermatological study involving 150 patients infected with Herpes labialis, and all three concentrations of propolis proved to be effective against Herpes labialis ($p < 0.0005$) for painless incrustation and local pains, but good tolerability was observed with the 0.5% concentration [125]. Another study conducted by Arenberger et al. showed the ability of propolis special extract (GH 2002) at 0.5% to treat episodes of herpes labialis virus versus 5% Acyclovir cream ($p < 0.0001$), and no allergic reactions, local irritations, or other adverse effects were observed (Table 4) [126]. Furthermore, propolis extract was evaluated in another double-blind, randomized, placebo-controlled trial, which reported the ability of propolis (200 mg three times daily for 7 days) to treat patients with dengue hemorrhagic fever virus, a faster recovery in platelet counts ($p = 0.006$), a greater decline in circulating TNF level ($p = 0.018$), and a shorter hospitalization period compared with placebo-treated patients ($p = 0.012$) (Table 4) [3].

Although propolis has plenty of biological and pharmacological properties, there is a lack of clinical reports on the effectiveness of propolis. Furthermore, some research has indicated that propolis is unsafe because it induces hypersensitivity and might induce adverse reactions such as allergic cheilitis and oral ulceration (Table 4) [128].

**8. In Silico Drug Discovery**

In seeking potential natural products to combat COVID-19 disease, the molecular docking technique was applied to portend the binding modes and affinities of 40 propolis derivatives towards five viral targets and one human target, namely 3CL\textsuperscript{pro}, RNA-dependent RNA polymerase (RdRp), papain-like protease (PLpro), receptor-binding domain (RBD) of the spike protein (S-protein), helicase (NSP13), and human angiotensin-converting enzyme 2 (ACE2). The technical details of the employed molecular docking calculations are described in References [129–136]. In brief, the crystal structures of SARS-CoV-2 3CL\textsuperscript{pro} (PDB code: 6LU7) [137], RdRp (PDB code: 6M71) [138], PL\textsuperscript{pro} (PDB code: 6W9C) [139], RBD (PDB code: 6M0J) [140], and NSP13 (PDB code: 5RMM) [141] were opted for as templates.
for all molecular docking calculations. For human ACE2, the 3D structure was taken from PDB code 6M0J [140]. For target preparation, all crystallographic water molecules, ions, heteroatoms, and ligands, if existing, were removed. All missing amino acid residues were constructed with the help of Modeller software [142]. Furthermore, the protonation states of the viral and human targets were inspected utilizing the H++ web server, and all missing hydrogen atoms were inserted [143]. The pdbqt files for the viral and human targets were then prepared in accordance with the AutoDock protocol [144]. The chemical structures of the investigated propolis derivatives were retrieved in SDF format from the PubChem database (https://pubchem.ncbi.nlm.nih.gov, accessed on 23 March 2021). Omega2 (software version 2.5.1.4, OpenEye Scientific Software, Inc., Santa Fe, NM, USA) was applied to generate the 3D structures of the investigated compounds [145,146]. All compounds were subsequently energetically minimized using the Merck Molecular Force Field 94 (MMFF94S) implemented inside SZYBKI software [147,148]. All molecular docking calculations were conducted using AutoDock4.2.6 software [149]. The maximum number of energy evaluations (eval) and the genetic-algorithm number (GA) were set to 25,000,000 and 250, respectively. All other docking parameters were kept at their default values. The docking grid box dimensions were set to 60 Å × 60 Å × 60 Å with a spacing value of 0.375 Å to encompass the active sites of the viral and human targets. The grid center was located at the center of the binding pockets of the targets. The Gasteiger method was applied to assign the atomic partial charges of the investigated propolis derivatives [150].

To predict the pharmacokinetic properties of the identified potential anti-viral propolis derivatives, the admetSAR server (http://lmmd.ecust.edu.cn/admetsar2/, accessed on 12 April 2021) was used. The pharmacokinetic properties included Lipinski’s rule of five, absorption, distribution, metabolism, excretion, and toxicity. The results gained were analyzed and compared to the reference values of the admetSAR pharmacokinetics expectation properties [151].

The docking scores and binding features of the 40 propolis derivatives against the viral and human targets were predicted and summarized in Table 5. For comparison purposes, the corresponding data for darunavir and favipiravir were predicted. Three- and two-dimensional representations of binding modes of the most potent propolis derivatives inside the active site of the viral and human targets are depicted in Figure 6. What is interesting about the data in Table 5 is that most propolis derivatives demonstrated good binding affinities against SARS-CoV-2 and ACE2 targets. The estimated docking scores ranged from −5.5 to −9.4 kcal/mol, from −4.9 to −8.2 kcal/mol, from −4.5 to −7.5 kcal/mol, from −5.0 to −9.4 kcal/mol, and from −5.5 to −10.4 kcal/mol with 3CLpro, PLpro, RdRp, NSP13, and ACE2, respectively. For the viral RDB target, propolis derivatives manifested moderate binding affinities with docking scores ranged from −4.0 to −7.2 kcal/mol. The observed potentiality of propolis derivatives towards the SARS-CoV-2 and ACE2 targets could be attributed to their capability of forming several hydrogen bonds, hydrophobic interactions, van der Waals, and pi-based interactions with the proximal amino acid residues inside the active site of these scrutinized targets. Interestingly, retusapurpurin A demonstrated the highest binding affinities towards 3CLpro, RdRp, RBD, NSP13, and ACE2 with docking scores of −9.4, −7.5, −7.2, −9.4, and −10.4 kcal/mol. More precisely, retusapurpurin A forms four hydrogen bonds with the key amino acids inside the active site of 3CLpro, RdRp, and NSP13 (Figure 6). Three hydrogen bonds were observed between retusapurpurin A and the proximal amino acid residues of ACE2, namely ASP206 (2.23 Å) and ASN210 (2.16 and 2.24 Å) (Figure 6). However, retusapurpurin A forms only two hydrogen bonds with TYR365 (1.71 Å) and ALA366 (2.14 Å) inside the active site of RBD of S-protein (Figure 6). For the PLpro target, baccharin displayed the highest binding affinities with a docking score of −8.2 kcal/mol. Eventually, baccharin exhibits three hydrogen bonds with ARG157 (2.17 Å), GLU196 (2.70 Å), and MET201 (2.20 Å) inside the active site of PLpro (Figure 6). Compared to retusapurpurin A and baccharin, darunavir revealed a good binding affinity towards 3CLpro, ACE2, and NSP13 with docking scores of −8.2, −8.5, and −7.1 kcal/mol, respectively. On the other hand, darunavir revealed a low binding affinity of −4.4, −3.8,
and −3.3 kcal/mol against RdRp, PL<sup>pro</sup>, and RBD of S-protein, respectively. In contrast, favipiravir manifested poor binding affinities with docking scores of −4.3, −4.0, −4.8, −4.4, −4.2, and −4.3 kcal/mol against 3CL<sup>pro</sup>, PL<sup>pro</sup>, RdRp, ACE2, RBD, and NSP13, respectively. The current data shed new light on the significance of retusapurpurin A and baccharin as promising SARS-CoV-2 and ACE2 inhibitors.

Figure 6. 3D and 2D representations of interactions of retusapurpurin A with proximal amino acid residues of SARS-CoV-2 (a) 3C-like protease (3CL<sup>pro</sup>), (b) RNA-dependent RNA polymerase (RdRp), (c) helicase (NSP13), (d) receptor-binding domain (RBD) of the spike protein, and (e) human angiotensin-converting enzyme 2 (ACE2), as well as (f) baccharin with papain-like protease (PL<sup>pro</sup>).
Table 5. Estimated docking scores (in kcal/mol) and binding features for 40 anti-viral compounds, darunavir, and favipiravir against SARS-CoV-2 3C-like protease (3CL<sup>pro</sup>), papain-like protease (PL<sup>pro</sup>), RNA-dependent RNA polymerase (RdRp), helicase (NSP13) receptor-binding domain (RBD) of the spike protein, and human angiotensin-converting enzyme 2 (ACE2).

| No. | Compound Name             | 3CL<sup>pro</sup> | PL<sup>pro</sup> | RdRp | NSP13 | RBD | ACE2 |
|-----|--------------------------|-------------------|-----------------|-------|-------|-----|------|
|     | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) |
| 1   | Darunavir                | −8.2              | GLU166 (1.94, 2.88 Å), LEU167 (1.96 Å) | −3.8  | GLU196 (2.18, 2.30 Å), MET199 (2.11 Å) | −4.4  | TYR619 (2.11 Å), ASP760 (1.83 Å), GLU111 (2.24, 2.26 Å) | −7.1  | LEU411 (2.93 Å), THR412 (2.18 Å), GLY414 (2.28 Å), LEU416 (2.12 Å), ASN556 (2.11 Å), ARG559 (1.97 Å) | −3.3  | GLU498 (1.89 Å), GLN507 (2.17 Å), SER508 (1.92 Å) | −8.5  | TYR202 (1.97 Å), GLU208 (3.02 Å), LYS562 (2.81 Å) |
| 2   | Favipiravir              | −4.3              | GLU166 (1.96, 2.26 Å), ARG188 (1.89 Å), THR190 (2.15 Å) | −4.0  | GLU196 (1.99 Å) | −4.8  | TRP617 (1.88 Å), ASP761 (1.96 Å), ALA762 (1.80 Å), TRP900 (2.20 Å) | −4.3  | ARG157 (2.18 Å), ASN515 (1.89 Å), THR531 (1.76 Å), ASP533 (1.99 Å) | −4.2  | LYS472 (2.05 Å), SER508 (2.07 Å), GLU498 (2.20 Å) | −4.4  | ASP206 (2.07 Å), GLU208 (1.98 Å), ALA396 (1.80 Å) |
| 1   | Retusapurpurin A         | −9.4              | LEU141 (2.22 Å), GLY143 (2.93 Å), SER144 (1.90 Å), CYS145 (2.25 Å) | −8.0  | GLU196 (2.17 Å), LEU196 (2.70 Å), MET201 (2.20 Å) | −7.5  | LYS621 (2.42 Å), LYS798 (2.96 Å), TRP900 (2.29 Å), GLU811 (2.23 Å) | −9.4  | ARG408 (1.88, 2.11 Å), ASN515 (1.99, 2.15 Å) | −7.2  | TYR365 (1.71 Å), ALA366 (2.14 Å) | −10.4 | ASP206 (2.23 Å), ASN210 (2.16, 2.24 Å) |
| 2   | Capillartemisin A        | −8.9              | HIS163 (1.99 Å), HIS164 (2.02 Å), THR190 (1.96 Å), GLN192 (2.32 Å) | −7.4  | ASP157 (1.81 Å), ASN260 (1.94 Å) | −6.7  | TYR619 (1.99 Å), ASP760 (2.08 Å), GLU811 (1.93 Å) | −7.0  | ARG177 (2.37 Å), ASN151 (2.91 Å), ASN515 (1.83, 1.98, 2.02 Å), THR531 (2.10 Å), HIS553 (2.40 Å) | −4.8  | TYR463 (1.91 Å), GLU498 (2.33 Å), GLN507 (2.01, 2.22 Å) | −8.9  | GLU208 (2.35 Å), ALA396 (1.84 Å), GLU564 (1.75 Å) |
| 3   | Artepillin C             | −8.8              | TYR54 (2.12, 2.34 Å), CYS44 (2.46 Å), GLU166 (2.25 Å), ASP187 (2.02 Å) | −8.0  | ASP157 (1.87 Å), ASN260 (1.87 Å) | −7.0  | ASP760 (2.09 Å), SER814 (1.89 Å) | −6.6  | ARG408 (2.02 Å), LEU411 (2.84 Å), LEU416 (2.11 Å) | −4.4  | TYR463 (2.08 Å) | −9.0  | GLU208 (2.35 Å), GLU564 (1.78 Å) |
| 4   | (E)-3-[4'-Hydroxy-3-(2- methylbut-3-en-1- yl)-5-(3-methylbut-2- en-1-yl)phenyl] propionic acid | −8.7              | MET49 (2.01 Å), TYR54 (2.24 Å), GLU166 (1.81, 2.13 Å) | −7.9  | ASP157 (1.89 Å), TYR257 (2.02 Å), ASN260 (1.91 Å) | −6.3  | SER759 (2.99 Å), ASP760 (1.74, 1.88 Å), TRP900 (1.96 Å), GLU811 (2.08 Å) | −6.4  | ARG408 (1.95 Å), LEU411 (2.12 Å), LEU416 (1.72 Å) | −2.7  | SER508 (1.92 Å) | −8.8  | GLN98 (1.86 Å), GLU208 (2.19 Å), GLU564 (2.06 Å) |
| 5   | Baccharin                | −8.7              | TYR54 (2.06, 2.33 Å), CYS44 (2.19 Å), LEU141 (2.32 Å), GLY143 (2.82 Å), ASP187 (2.45 Å), GLN189 (1.90 Å) | −8.2  | ASP157 (1.87 Å), ARG159 (2.01 Å), TYR261 (2.00 Å) | −6.8  | ASP618 (2.19 Å), ASP760 (1.99 Å), SER814 (2.07 Å) | −6.5  | ARG177 (2.48 Å), ASN178 (2.80 Å), SER845 (2.01 Å), ASN515 (1.93 Å), THR531 (1.92 Å) | −5.5  | TYR463 (1.89 Å), GLU498 (1.88 Å), SER508 (1.87 Å), LEU506 (2.13 Å), GLN507 (2.17, 2.60 Å) | −8.5  | GLN98 (2.23 Å), GLU208 (3.07 Å), SER563 (2.01 Å), TRP566 (2.19 Å) |
| No. | Compound Name                      | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) |
|-----|------------------------------------|---------------------------|-----------------------------------------------|---------------------------|-----------------------------------------------|---------------------------|-----------------------------------------------|---------------------------|-----------------------------------------------|---------------------------|-----------------------------------------------|
| 6   | (E)-2,3-Dihydroconiferyl p-coumarate | -8.6                      | LEU141 (1.96 Å), GLY143 (3.06 Å), SER144 (2.14 Å), CYS145 (2.66 Å), THR190 (2.05 Å) | -7.6                      | LYS150 (1.97 Å), LEU155 (2.01 Å), ASP259 (1.94 Å) | -5.7                      | ASP760 (2.14 Å), CYS813 (2.63 Å), SER814 (1.96 Å) | -6.8                      | ASN515 (2.52 Å), ASP533 (2.05 Å) | -3.0                      | GLU498 (1.83 Å), GLN507 (2.38 Å) |
| 7   | Quercetin                          | -8.5                      | HIS164 (2.23 Å), ASP187 (1.91 Å), THR190 (2.08 Å), GLN192 (1.51 Å) | -6.8                      | LYS150 (2.36 Å), GLU160 (2.28 Å), ASN260 (1.79 Å), TYR266 (2.96 Å), THR294 (2.09 Å), ALA239 (3.01 Å) | -6.6                      | TYR619 (1.99, 2.03 Å), ASP761 (2.10 Å), GLU811 (2.33 Å) | -6.9                      | ASN178 (2.25 Å), LEU416 (1.94 Å) | -4.7                      | PHE361 (2.00, 2.08 Å), TYR365 (2.89 Å), TYR463 (2.16 Å) |
| 8   | Sakuranetin                         | -8.5                      | HIS164 (2.22 Å), THR190 (2.01 Å) | -6.9                      | ASP295 (1.65 Å) | -6.7                      | TYR619 (1.86 Å), ASP761 (2.43 Å) | -6.9                      | PRO405 (1.84 Å), ASN515 (1.96 Å) | -4.9                      | SER363 (1.93 Å), TYR365 (1.77 Å), ASN364 (1.99, 2.73 Å) |
| 9   | Kaempferol                          | -8.4                      | HIS164 (2.04 Å), ASP187 (1.99 Å), THR190 (1.81 Å) | -7.2                      | LEU255 (1.91 Å), ASN260 (1.96 Å), THR294 (1.83 Å) | -6.4                      | TRP617 (2.45 Å), TYR619 (1.84 Å), ASP761 (2.27 Å), TRP800 (2.12 Å) | -6.9                      | ASN178 (2.03 Å), LEU416 (1.89 Å), ASN556 (1.87 Å), ARG559 (2.70 Å) | -4.9                      | SER363 (1.93 Å), TYR365 (1.77 Å), ASN364 (1.99, 2.73 Å) |
| 10  | Isohamnetin                         | -8.3                      | HIS164 (2.36 Å), ASP187 (1.98 Å), THR190 (2.07 Å) | -6.8                      | GLU160 (1.99 Å), ASN260 (1.89 Å), TYR266 (2.16 Å), THR294 (1.84 Å) | -6.5                      | LYS261 (2.32 Å), CYS262 (2.19 Å), ASP761 (1.90 Å), GLU811 (2.27 Å) | -6.6                      | ASN178 (2.15 Å), ARG408 (2.18 Å), PHE361 (1.83 Å), THR353 (1.76 Å), ASN515 (2.89 Å) | -4.9                      | SER363 (2.05 Å), TYR365 (1.75 Å), ASN464 (2.02, 2.63 Å) |
| 11  | Sakuranetin-4′-methyl ether         | -8.2                      | HIS164 (2.25 Å), GLN192 (2.21 Å) | -7.0                      | ARG159 (1.93 Å), THR294 (1.87 Å) | -6.5                      | ASP761 (2.40 Å) | -7.0                      | ARG408 (2.13 Å), ASN515 (2.12, 2.30 Å) | -4.9                      | TYR365 (2.21 Å), ASN464 (2.22, 2.26 Å) | -8.8                      | ASN210 (1.96, 1.98 Å) |
| 12  | Pinobanksin-3-acetate               | -8.1                      | HIS164 (2.21 Å), GLU166 (1.96 Å), ASP187 (1.87 Å) | -6.8                      | TYR266 (2.92 Å), ASP295 (2.08 Å) | -6.0                      | LYS261 (2.45, 2.77 Å), CYS262 (1.89 Å), LYS978 (2.21 Å) | -6.7                      | ASN178 (2.22 Å), THR409 (2.00 Å), ARG559 (2.29 Å) | -5.4                      | PHE361 (1.71 Å), TYR365 (2.09 Å), ASN464 (2.14 Å) | -8.8                      | ASN210 (2.05, 2.16, 2.92 Å), SER563 (2.08 Å) |
| 13  | Calycosin                           | -8.1                      | ASP187 (2.0 Å), THR190 (2.15 Å) | -7.4                      | LYS150 (2.42 Å), GLU160 (2.29 Å), THR294 (1.92 Å) | -6.2                      | LYS619 (2.59 Å), GLY161 (2.22 Å), ASP263 (2.08 Å), LYS978 (2.33 Å) | -7.0                      | ASN176 (1.97, 2.90 Å), TYR197 (1.78 Å), ASP533 (1.84 Å) | -5.1                      | PHE361 (2.10 Å), TYR365 (1.65 Å) | -8.7                      | ASP206 (2.10 Å), ASN210 (1.73 Å), LYS562 (2.10 Å), SER563 (2.08 Å), GLU564 (3.04 Å) |

Table 5. Cont.
| No. | Compound Name          | Docking Score | Binding Features (Hydrogen Bond Length in Å) | Docking Score | Binding Features (Hydrogen Bond Length in Å) | Docking Score | Binding Features (Hydrogen Bond Length in Å) | Docking Score | Binding Features (Hydrogen Bond Length in Å) | Docking Score | Binding Features (Hydrogen Bond Length in Å) | Docking Score | Binding Features (Hydrogen Bond Length in Å) |
|-----|------------------------|---------------|-----------------------------------------------|---------------|-----------------------------------------------|---------------|-----------------------------------------------|---------------|-----------------------------------------------|---------------|-----------------------------------------------|---------------|-----------------------------------------------|
| 14  | Myricetin              | −8.0          | ARG159 (3.01, 3.02 Å), ALA239 (2.84 Å), TYR257 (2.79 Å), ASP760 (1.92 Å), ASP761 (1.95 Å), GLU811 (2.36 Å) | −7.0          | TYR619 (2.22 Å), LYS621 (2.83 Å), ASP760 (1.92 Å), ASP761 (1.95 Å), GLU811 (2.36 Å) | −6.8          | ASN178 (2.09 Å), PRO405 (1.80 Å), LEU416 (1.85 Å), ASN556 (1.91 Å), ARG559 (2.77 Å) | −7.0          | ARG360 (2.95 Å), PHE361 (1.98 Å), TYR363 (2.17 Å), ASN464 (1.84 Å) | −8.0          | ASP200 (1.88 Å), ASN210 (1.99 Å), ALA396 (1.82 Å), GLU564 (3.02 Å) |
| 15  | Apigenin               | −8.0          | HIS164 (2.39 Å), ASP187 (1.96 Å), THR190 (1.99 Å) | −6.5          | LYS150 (1.96 Å), TYR261 (2.71 Å), THR294 (1.97 Å) | −6.8          | LEU416 (1.95 Å), ASN556 (1.86, 2.19 Å) | −5.3          | ASN363 (2.06 Å), TYR365 (1.70 Å), ASN464 (1.96, 2.65 Å) | −8.7          | ASP200 (1.92 Å), ASN210 (1.83, 1.86 Å), SER563 (2.00 Å) |
| 16  | Daidzein               | −8.0          | HIS164 (3.09 Å), THR190 (2.04 Å) | −6.8          | LEU155 (2.69 Å), THR294 (1.87 Å) | −5.9          | ASN263 (1.68 Å), TYR619 (2.13 Å), ASP761 (1.71 Å) | −6.8          | ALA406 (2.13 Å), ASN515 (1.96 Å) | −5.9          | PHE361 (1.69 Å), TYR365 (2.10 Å), ASN364 (1.81 Å), LEU482 (2.07 Å) | −7.9          | GLN198 (2.58 Å), GLU564 (1.91 Å) |
| 17  | Chrysin                | −7.8          | GLU166 (2.09 Å), THR190 (1.91 Å) | −6.9          | ARG159 (1.79, 2.19, 2.94 Å), THR294 (1.84 Å) | −6.2          | LYS621 (1.96 Å), ASP206 (1.91, 2.17 Å) | −7.1          | ASN178 (1.96, 2.12 Å), ASP533 (2.07 Å) | −5.6          | SER363 (2.04 Å), TYR363 (1.74 Å), ASN464 (2.03, 2.71 Å) | −8.5          | ASN210 (2.03, 2.07 Å), SER563 (2.02 Å), GLU564 (3.03 Å) |
| 18  | Liquiritigenin         | −7.8          | ASP187 (1.95 Å), THR190 (1.96 Å) | −7.0          | GLY156 (1.99 Å), ASP285 (1.84 Å) | −6.2          | LYS621 (2.10 Å), CYS622 (2.95 Å), ASP206 (2.07 Å), ASP760 (2.35 Å) | −7.0          | ASN178 (2.08 Å), LEU416 (2.31, 2.54 Å), ASP533 (2.26 Å) | −5.9          | GLU420 (1.77 Å), TYR463 (1.98 Å), GLY510 (1.85 Å) | −8.4          | ASP188 (1.92 Å), GLN192 (1.79 Å), SER545 (2.04 Å) |
| 19  | Luteolin               | −7.8          | TYR54 (2.76 Å), HIS164 (2.17 Å), THR190 (2.06 Å), GLN192 (2.42 Å) | −7.1          | LYS150 (2.43 Å), GLU166 (2.29 Å), TYR266 (2.17 Å), THR294 (1.90, 2.04 Å) | −6.9          | TYR619 (2.20 Å), LEU416 (2.09 Å), ASN556 (2.07 Å) | −6.9          | ASP78 (2.30 Å), TYR365 (2.45 Å), TYR463 (2.16 Å) | −4.9          | PHE361 (1.77, 1.96 Å), TYR365 (2.45 Å), ASN464 (2.16 Å) | −8.9          | ASP206 (1.88, 1.98 Å), ASN210 (1.82, 1.86 Å), SER563 (2.02 Å) |
| 20  | Vestitone              | −7.8          | HIS163 (2.04 Å), GLU166 (2.11 Å), ASP187 (2.54 Å) | −7.5          | ARG159 (1.94 Å), TYR261 (2.15, 2.44 Å) | −5.9          | ASP263 (1.99 Å), ASP760 (2.13 Å) | −7.5          | ASP533 (1.68 Å), TYR365 (1.95 Å) | −7.6          | LYS94 (1.74 Å), ALA396 (2.11 Å), TRP566 (2.29 Å) |
| 21  | Caffeic acid phenethyl ester (CAPE) | −7.8 | LEU141 (2.11, 2.12 Å), GLY143 (2.44 Å), SER144 (2.15 Å), HIS163 (2.09 Å), GLU166 (2.35 Å) | −7.5          | TYR266 (1.97 Å), ASP285 (1.78, 2.13 Å) | −6.5          | TYR619 (2.13, 2.21 Å), ASP760 (1.96 Å), CYS813 (2.72 Å), SER814 (2.03 Å) | −6.5          | THR415 (1.83, 2.09 Å) | −4.0          | GLU498 (1.97, 2.04 Å) | −8.2          | ASN210 (1.95, 2.47 Å), ALA396 (1.95, 1.97 Å), TRP566 (2.29 Å) |
| 22  | Formononetin           | −7.7          | PHE140 (2.66 Å), CY5145 (2.38 Å), GLU166 (1.97 Å) | −7.2          | THR294 (1.77 Å) | −6.2          | LYS621 (1.81 Å), LYS978 (1.94 Å) | −6.8          | ASN515 (1.94 Å) | −5.3          | PHE361 (1.69 Å), TYR365 (2.11 Å), ASN464 (1.81 Å) | −7.6          | TYR166 (2.22 Å), GLU208 (1.70 Å), ASN210 (2.11 Å) |
| No. | Compound Name | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) |
|-----|---------------|---------------------------|-----------------------------------------------|---------------------------|-----------------------------------------------|---------------------------|-----------------------------------------------|---------------------------|-----------------------------------------------|---------------------------|-----------------------------------------------|
| 23  | Pinocembrin   | −7.7                      | GLU166 (2.12 Å), THR190 (1.76 Å)              | −7.0                      | ARG159 (1.82 Å), TRP617 (3.08 Å)              | −6.0                      | TRP617 (1.92 Å), ALA762 (1.81 Å)              | −7.3                      | ASN718 (1.97 Å), ASP533 (2.02 Å)            | −5.1                      | SER365 (2.02 Å), ASN646 (2.11 Å)           |
| 24  | Isoliquiritigenin | −7.6                     | HIS164 (2.36 Å), ASP187 (1.98 Å), THR190 (2.07 Å) | −6.8                      | ALA239 (2.33 Å), TYR617 (2.12 Å)             | −6.0                      | ALA406 (2.09 Å), ARG408 (2.37 Å)             | −7.1                      | PHE361 (1.95 Å), TYR365 (1.90 Å)           | −4.3                      | ASN210 (1.96 Å), SER563 (2.15 Å)           |
| 25  | Violanone     | −7.6                      | CYS44 (1.91 Å)                                | −7.3                      | LEU155 (2.04 Å), THR294 (2.02 Å)             | −6.1                      | ASP164 (1.89 Å), TYR179 (2.11 Å)             | −7.3                      | ARG408 (2.12 Å), ASN515 (2.09 Å)           | −4.9                      | SER563 (1.86, 1.96 Å), ALA239 (2.13 Å), TRP566 (2.24 Å) |
| 26  | Drupanin      | −7.5                      | HIS164 (1.96 Å), THR190 (1.83 Å), GLN192 (2.06 Å) | −7.0                      | ASP157 (1.87 Å), ASN260 (1.94 Å)             | −6.3                      | ASP760 (1.85 Å), LEU155 (1.72 Å)             | −6.1                      | GLU498 (1.68 Å), ASN210 (2.10 Å)           | −7.8                      | GLU564 (1.70 Å)                            |
| 27  | Galangin      | −7.5                      | HIS164 (2.21 Å), ASP187 (1.92 Å)              | −6.8                      | ARG159 (1.85 Å), THR294 (1.73 Å)             | −5.8                      | LEU146 (1.91 Å), ASN566 (2.15 Å)             | −6.6                      | ARG408 (2.12 Å), SER485 (1.91 Å)           | −5.3                      | SER563 (2.06 Å), ALA239 (2.04 Å), SER563 (2.35 Å) |
| 28  | Pinobaskin    | −7.5                      | HIS164 (2.23 Å), ASP187 (1.90 Å)              | −6.7                      | ARG159 (1.83 Å), THR294 (1.73 Å)             | −5.6                      | LEU146 (1.91 Å), ASN566 (1.85 Å)             | −6.6                      | ARG408 (2.12 Å), SER485 (1.91 Å)           | −5.3                      | SER563 (2.06 Å), ALA239 (2.13 Å), TRP566 (2.35 Å) |
| 29  | Pinostrobin   | −7.4                      | SER144 (2.92 Å), HIS163 (1.98 Å)              | −6.9                      | ARG159 (1.80 Å), LEU155 (2.05 Å)             | −6.1                      | ARG159 (1.80 Å), LEU155 (2.05 Å)             | −6.7                      | ARG159 (1.93 Å), SER563 (2.05 Å)           | −5.1                      | TYR365 (2.20 Å), GLU564 (2.32 Å)           |
| 30  | Biochanin A   | −7.4                      | THR190 (1.78 Å), GLN192 (3.06 Å)              | −7.5                      | ARG159 (1.93 Å), LEU155 (2.05 Å)             | −6.3                      | TYR619 (3.05 Å), LEU155 (2.05 Å)             | −7.0                      | ASN178 (2.14 Å), ASN515 (2.16 Å)           | −5.1                      | PHE361 (1.75 Å), ASN646 (1.78 Å)           |
| 31  | Pratensein    | −7.4                      | LEU141 (2.17 Å), GLX143 (2.16 Å), ASP187 (2.85 Å) | −7.6                      | LEU155 (2.09 Å), THR294 (1.90 Å)             | −6.9                      | LEU155 (2.09 Å), SER485 (2.11 Å)             | −7.2                      | ASN178 (2.16 Å), ASN515 (1.96 Å)           | −4.9                      | GLU498 (1.83 Å), GLN507 (2.38 Å)           |

Table 5. Cont.
| No. | Compound Name                          | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) | Docking Score (kcal/mol) | Binding Features (Hydrogen Bond Length in Å) |
|-----|---------------------------------------|--------------------------|---------------------------------------------|--------------------------|---------------------------------------------|--------------------------|---------------------------------------------|--------------------------|---------------------------------------------|--------------------------|---------------------------------------------|
| 32  | 2,2-Dimethyl chromene-6-propenonic acid | −7.3                     | THR190 (1.76 Å)                             | −7.3                     | ASP157 (2.07 Å)                             | −6.4                     | TRP617 (2.79 Å), ASP761 (1.88 Å)             | −6.4                     | GLU178 (2.24 Å), THR531 (2.40 Å), ASN515 (2.03, 2.22 Å), ARG539 (2.99 Å) | −5.6                     | TYR467 (1.84 Å)                             |
| 33  | Neovestitol                           | −7.2                     | GLU166 (2.03 Å)                             | −7.1                     | ARG159 (2.01 Å), TYR261 (2.11 Å)             | −5.9                     | LYS798 (2.13 Å)                             | −6.8                     | ALA416 (2.16 Å), ARG408 (2.27 Å)             | −5.5                     | SER508 (2.09 Å)                             | −7.4                     | ASN210 (1.80 Å, 2.04 Å)                      |
| 34  | Rutin                                 | −7.2                     | GLY143 (2.18 Å), SER114 (2.62 Å), CYS145 (1.83 Å), HSY163 (1.99 Å) | −7.0                     | TYR266 (1.76 Å), ASP296 (1.82 Å)             | −6.5                     | ASP761 (2.23 Å)                             | −7.3                     | ARG408 (2.10 Å), THR415 (1.90 Å), LEU 416 (2.05 Å), ARG539 (1.89, 2.63 Å) | −5.6                     | ARG417 (2.14 Å), GLN507 (2.33 Å), SER508 (2.08 Å), GLY510 (1.97 Å) | −7.7                     | LYS94 (2.55 Å)                              |
| 35  | Medicarpin                            | −6.5                     | GLY143 (2.18 Å), SER114 (2.62 Å), CYS145 (1.83 Å), HSY163 (1.99 Å) | −7.0                     | TYR266 (1.76 Å), ASP296 (1.82 Å)             | −6.5                     | ASP761 (2.23 Å)                             | −7.3                     | ARG408 (2.10 Å), THR415 (1.90 Å), LEU 416 (2.05 Å), ARG539 (1.89, 2.63 Å) | −5.6                     | ARG417 (2.14 Å), GLN507 (2.33 Å), SER508 (2.08 Å), GLY510 (1.97 Å) | −7.7                     | LYS94 (2.55 Å)                              |
| 36  | Ferulic acid                          | −5.9                     | CYS44 (2.48 Å), TYR54 (2.20, 2.44 Å), GLU166 (2.25 Å), ASP187 (2.01 Å) | −5.3                     | ASP157 (1.88 Å), ASN260 (2.13 Å)             | −4.9                     | TRP617 (2.77 Å), ASP761 (1.83 Å)             | −6.1                     | GLY201 (2.11, 2.79 Å), SER484 (1.87 Å), ASN515 (1.94 Å) | −5.0                     | GLU420 (1.62 Å), GLY510 (1.21 Å)             | −6.1                     | ASN210 (1.76, 1.83 Å), ALA396 (1.88 Å)       |
| 37  | m-Coumaric acid                       | −5.8                     | CYS44 (1.74 Å), TYR54 (2.01 Å), HSY163 (2.04 Å), ASP187 (1.82 Å) | −5.0                     | ARG159 (2.01 Å), ASN260 (2.15 Å), TYR261 (1.85 Å) | −5.5                     | ASP761 (1.95 Å), ASP761 (1.99 Å)             | −6.8                     | ASP482 (2.11 Å), GLN208 (1.96 Å), SER485 (1.77 Å), ASN515 (1.92 Å) | −5.0                     | ASP481 (1.78 Å), GLU485 (1.83 Å)             | −6.0                     | ASN210 (1.78 Å, ALA396 (1.86 Å), TRP566 (2.23 Å) |
| 38  | p-Coumaric acid                       | −5.8                     | CYS44 (1.73 Å), TYR54 (2.04 Å), HSY163 (2.04 Å), ASP187 (1.83 Å) | −5.2                     | ASP157 (1.99 Å), ASN260 (1.89 Å)             | −4.9                     | ASP761 (1.81 Å), TRP800 (2.45 Å)             | −5.3                     | ASN176 (2.88 Å), SER485 (2.06 Å)             | −4.3                     | TYR467 (2.06 Å), SER508 (1.78 Å), TYR519 (1.78 Å) | −5.5                     | ASN210 (2.05 Å, ALA396 (1.82 Å), TRP566 (2.22 Å) |
| 39  | Caffeic acid                          | −5.7                     | MET49 (1.95 Å), TYR54 (2.15 Å), GLU166 (2.05, 2.19 Å) | −4.9                     | ASN260 (1.79 Å), TRP266 (2.30 Å), THR294 (1.78, 1.90 Å) | −5.2                     | TRP617 (3.09 Å), ASP761 (1.73, 1.89 Å), HIS163 (2.07 Å), GLU811 (1.84 Å) | −6.5                     | LYS201 (2.11 Å), ASP482 (1.95 Å), SER485 (1.79 Å), ASN515 (1.81 Å) | −4.4                     | ARG417 (2.38 Å), GLU420 (2.72 Å), GLY510 (1.93, 2.04 Å) | −6.3                     | ASN210 (1.96, 1.99 Å, ALA396 (1.82 Å), TRP566 (2.54 Å) |
| 40  | Trans-Cinnamic acid                   | −5.5                     | CYS44 (1.74 Å), TYR54 (2.01 Å), ASP187 (1.82 Å) | −5.0                     | ARG159 (1.78, 2.10 Å), TYR261 (1.97 Å)       | −5.1                     | TRP617 (2.73 Å), ASP761 (1.81 Å), TRP800 (2.42 Å) | −5.0                     | ASN176 (2.57 Å), SER485 (1.82 Å)             | −4.7                     | TYR467 (1.87 Å), SER508 (1.81 Å)             | −5.5                     | ASN210 (1.94 Å)                              |
The pharmacokinetics, physicochemical, and toxicological properties, as summarized in Table 6, provide a quantitative analysis of what the human body performs to an administered molecule. Based on Lipinski’s rule of five (RO5), retusapurpurin A and baccharin obey the criteria for orally active drugs.

Table 6. List of physicochemical, ADME, and toxicological properties of retusapurpurin A and baccharin.

| Compound Name       | MW  a  | Log P b | TPSA c | nON d  | nOHNH e | RBs f  | BBB g   | Caco2 h | HIA i  | AMES Toxicity | Carcinogenicity |
|---------------------|-------|--------|--------|--------|--------|--------|--------|--------|--------|------------|----------------|
| Retusapurpurin A    | 522.6 | 6.2    | 98.4   | 7      | 2      | 5      | 0.41   | 74.84  | 98.97  | Non toxic   | Non carcinogenic |
| Baccharin           | 318.46| 3.16   | 77.75  | 3      | 3      | 7      | 0.87   | 57.33  | 97.10  | Non toxic   | Non carcinogenic |

a Molecular weight ≤ 500 g/mol. b Partition coefficient logarithm between n-octanol and water ≤ 5. c Topological polar surface area ≤ 140 A². d Number of hydrogen bond acceptors ≤ 10. e Number of hydrogen bond donors ≤ 5. f Number of rotatable bonds ≤ 10. g Blood–brain barrier ranged from −3 to 1.2. h Permeability < 25 (poor) and >500 (great). i % Human intestinal absorption < 25 (poor) and >80 (high).

It can be seen from the data in Table 6 that retusapurpurin A and baccharin showed a great Caco-2 permeability. Additionally, retusapurpurin A and baccharin demonstrated a great human intestinal absorption (HIA) with an estimated HIA value of ≈97% (Table 6). For the blood–brain barrier (BBB permeability), retusapurpurin A and baccharin were predicted to pass the BBB easily. Ultimately, retusapurpurin A and baccharin were non-carcinogenic and non-toxic. Overall, the predicted results displayed that the ADMET properties of retusapurpurin A and baccharin are extremely satisfying, as presented in Table 6. Consequently, retusapurpurin A and baccharin should be considered as prospective drug candidates against COVID-19.

9. Conclusions

Propolis is among the few natural remedies that have been utilized for centuries, and modern laboratory investigations have confirmed that the effectiveness of propolis originates from its extracts and derivatives against multiple disease models, including viral infections. These therapeutic effects are attributable to a high content with pharmacologically active molecules, mainly concentrations of bioactive flavonoids, phenolic acids, and their esters. These components have significant activities that target a myriad of pathological and reparative processes, including immune signaling pathways. The demonstrated efficacy against a wide range of human viruses has provided a rationale, and paved the way, for studies on the efficacy of propolis to be tested against SARS-CoV-2. Furthermore, 40 propolis derivatives have shown a high affinity SARS-CoV-2 proteins and the human target ACE2, with one, retusapurpurin A, demonstrating particularly potent binding to SARS-CoV-2 3CLpro, RdRp, ACE2, RBD, and NSP13 inhibitor. These results suggest that retusapurpurin A and other components such as baccharin are promising, and with further investigation, they could be used as potential weapons in the fight against the pandemic and as therapeutic candidates for COVID-19 treatment.

In addition to viral infection, propolis has anti-inflammatory and immunomodulatory activities. Propolis was proven to be effective through different mechanisms against several immune-mediated models of cancer and immune-related diseases, i.e., celiac disease, uveoretinitis, allergic asthma, rheumatoid arthritis, leishmaniasis, microbial infections, and cancer in vitro and in vivo. There is, however, little knowledge. While there have been few studies on the clinical efficacy of propolis and its effects on human health, further investigations are needed to determine its application. Forty propolis derivatives were investigated in in silico preparations against five SARS-CoV-2 and human ACE2 targets as anti-COVID-19 drug candidates with the help of the molecular docking technique. The binding affinities unveiled that retusapurpurin A is a potent SARS-CoV-2 3CLpro, RdRp, ACE2, RBD, and NSP13 inhibitor. However, baccharin demonstrated the highest binding affinity against SARS-CoV-2 PLpro. Moreover, drug-likeness and ADMET properties were predicted for the most potent compounds and demonstrated satisfactory pharmacokinetics,
physicochemical parameters, and toxicological properties. These results suggest that retusapurpurin A and baccharin can be further investigated as convenient therapeutic treatments for COVID-19 disease, and clinical trials are feasible due to the generally good safety profiles of propolis derivatives.

**Author Contributions:** Writing—original draft preparation N.Y., A.A.A.E.-W., R.G., O.M.K. and A.S.; Molecular docking, M.A.A.I and M.F.M. Writing—review and editing, Z.G., X.Z., A.F.M.A., S.H.D.M., M.F.A., H.S.A., S.A.M.K. and H.R.E.-S.; Project administration, H.R.E.-S.; Supervision, S.A.M.K. and H.R.E.-S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Swedish Research Council Vetenskapsrådet (VR grant 2016–05885).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** Authors are very grateful to the Swedish Research links Grant VR 2016–05885 and the Department of Molecular Biosciences, Wenner-Grens Institute, Stockholm University, Sweden, for the financial support.

**Conflicts of Interest:** The authors declare that they have no conflict of interest.

**References**

1. Pavlovic, R.; Borgonovo, G.; Leoni, V.; Giupponi, L.; Ceciliani, G.; Sala, S.; Bassoli, A.; Giorgi, A. Effectiveness of different analytical methods for the characterization of propolis: A case of study in Northern Italy. *Molecules* 2020, 25, 504. [CrossRef]

2. Costa, A.G., Jr.; Yoshida, N.C.; Garcez, W.S.; Perdomo, R.T.; Matos, M.d.F.C.; Garcez, F.R. Metabolomics approach expands the classification of propolis samples from midwest Brazil. *J. Nat. Prod.* 2020, 83, 333–343. [CrossRef]

3. Soroy, L.; Bagus, S.; Yongkie, I.P.; Djoko, W. The effect of a unique propolis compound (Propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever. *Infect. Drug Resist.* 2014, 7, 323–329.

4. Jasprica, I.; Mornar, A.; Debeljak, Ž.; Smolčič-Bubalo, A.; Medić-Šarić, M.; Mayer, L.; Romić, Ž.; Bučan, K.; Balog, T.; Sobočanec, S. In vivo study of propolis supplementation effects on antioxidative status and red blood cells. *J. Ethnopharmacol.* 2007, 110, 548–554. [CrossRef] [PubMed]

5. Sforcin, J.M.; Bankova, V. Propolis: Is there a potential for the development of new drugs? *J. Ethnopharmacol.* 2011, 133, 253–260. [CrossRef] [PubMed]

6. Paulino, N.; Dantas, A.P.; Bankova, V.; Longhi, D.T.; Scremin, A.; de Castro, S.L.; Calixto, J.B. Bulgarian propolis induces analgesic and anti-inflammatory effects in mice and inhibits in vitro contraction of airway smooth muscle. *J. Pharmacol. Sci.* 2003, 93, 307–313. [CrossRef]

7. Yuan, J.; Liu, J.; Hu, Y.; Fan, Y.; Wang, D.; Guo, L.; Nguyen, T.L.; Zhao, X.; Liu, X.; Liu, C. The immunological activity of propolis flavonoids liposome on the immune response against ND vaccine. *Int. J. Biol. Macromol.* 2012, 51, 400–405. [CrossRef] [PubMed]

8. Burdock, G.A. Review of the biological properties and toxicity of bee propolis (propolis). *Food Chem. Toxicol.* 1998, 36, 347–363. [CrossRef]

9. Skaba, D.; Morawiec, T.; Tanasiewicz, M.; Mertas, A.; Bobela, E.; Szliszka, E.; Skucha-Nowak, M.; Dawiec, M.; Yamamoto, R.; Ishiai, S.; et al. Influence of the toothpaste with Brazilian ethanol extract propolis on the oral cavity health. *Evid. Based Complement. Altern. Med.* 2013, 2013, 215391. [CrossRef]

10. Sforcin, J.M. Biological properties and therapeutic applications of propolis. *Phyther. Res.* 2016, 30, 894–905. [CrossRef] [PubMed]

11. Pasupuleti, V.R.; Sammugam, L.; Ramesh, N.; Gan, S.H. Honey, propolis, and royal jelly: A comprehensive review of their biological actions and health benefits. *Oxid. Med. Cell. Longevity.* 2017, 2017. [CrossRef]

12. Amoros, M.; Sauvager, F.; Girre, L.; Cormier, M. In vitro antiviral activity of propolis. *Apidologie* 1992, 23, 231–240. [CrossRef]

13. Schnitzler, P.; Neuner, A.; Nolkeremper, S.; Zundel, C.; Nowack, H.; Sensch, K.H.; Reichling, J. Antiviral activity and mode of action of propolis extracts and selected compounds. *Phyther. Res.* 2010, 24, S20–S28. [CrossRef] [PubMed]

14. Kujumgiev, A.; Tsvetkova, I.; Serkedjieva, Y.; Bankova, V.; Christov, R.; Popov, S. Antibacterial, antifungal and antiviral activity of propolis from different geographic origin. *J. Ethnopharmacol.* 1999, 64, 235–240. [CrossRef]

15. Kwon, M.J.; Shin, H.M.; Perumalsamy, H.; Wang, X.; Ahn, Y.-J. Antiviral effects and possible mechanisms of action of constituents from Brazilian propolis and related compounds. *J. Apic. Res.* 2020, 59, 413–425. [CrossRef]

16. Serkedjieva, J.; Manolova, N.; Bankova, V. Anti-influenza virus effect of some propolis constituents and their analogues (esters of substituted cinnamic acids). *J. Nat. Prod.* 1992, 55, 294–297. [CrossRef]

17. Debiaggi, M.; Tateo, F.; Pagani, L.; Luini, M.; Romero, E. Effects of propolis flavonoids on virus infectivity and replication. *Microbiologica* 1990, 13, 207–213. [PubMed]
18. Refaat, H.; Mady, F.M.; Sarhan, H.A.; Rateb, H.S.; Alaaeldin, E. Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19. Int. J. Pharm. 2020, 120028. [CrossRef]

19. Sahlan, M.; Irdiani, R.; Flamandita, D.; Aditama, R.; Alfarraj, S.; Javed Ansari, M.; Cahya Khayrani, A.; Kartika Pratami, D.; Lischer, K. Molecular interaction analysis of Sulawesi propolis compounds with SARS-CoV-2 main protease as preliminary study for COVID-19 drug discovery. J. King Saud Univ. Sci. 2020, 101234. [CrossRef]

20. Hashem, H. In silico approach of some selected honey constituents as SARS-CoV-2 main protease (COVID-19) inhibitors. ChemRxiv. 2020. [CrossRef]

21. Zabaiou, N.; Fouache, A.; Trousson, A.; Baron, S.; Zellagui, A.; Lahouel, M.; Lobacaro, J.-M.A. Biological properties of propolis extracts: Something new from an ancient product. Chem. Phys. Lipids 2017, 207, 214–222. [CrossRef]

22. Zaccaria, V.; Garzarella, E.U.; Di Giovanni, C.; Galeotti, F.; Gisone, L.; Campoccia, D.; Volpi, N.; Arciola, C.R.; Daglia, M. Multi dynamic extraction: An innovative way to obtain a standardized chemically and biologically reproducible polyphenol extract from poplar-type propolis to be used for its anti-infective properties. Materials (Basel) 2019, 12, 3746. [CrossRef]

23. Popova, M.; Trusheva, B.; Bankova, V. Propolis of stingless bees: A phytochemist’s guide through the jungle of tropical biodiversity. Phytomedicine 2019, 86, 153098. [CrossRef]

24. Tolba, M.F.; Azab, S.S.; Khalifa, A.E.; Abdel-Rahman, S.Z.; Abdel-Naim, A.B. Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: A review on its anti-inflammmatory, neuroprotective, hepatoprotective, and cardioprotective effects. IUBMB Life 2013, 65, 699–709. [CrossRef] [PubMed]

25. Banskota, A.H.; Tezuka, Y.; Kadota, S. Recent progress in pharmacological research of propolis. Phyther. Res. 2001, 15, 561–571. [CrossRef] [PubMed]

26. Picolotto, A.; Pergher, D.; Pereira, G.P.; Machado, K.G.; da Silva Barud, H.; Roesch-Ely, M.; Gonzalez, M.H.; Tasso, L.; Figueiredo, J.G.; Moura, S. Bacterial cellulose membrane associated with red propolis as phytomodulator: Improved healing effects in experimental models of diabetes mellitus. Biomed. Pharmacother. 2019, 112, 108640. [CrossRef] [PubMed]

27. Siheri, W.; Alenezi, S.; Tusiimire, J.; Watson, D.G. The chemical and biological properties of propolis. In Bee Products—Chemical and Biological Properties; Alvarez-Suarez, J.M., Ed.; Springer International Publishing: Cham, Switzerland, 2017; pp. 137–178. ISBN 978-3-319-59689-1.

28. Granados-Pineda, J.; Uribe-Uribe, N.; García-López, P.; Ramos-Godínez, M.D.P.; Rivero-Cruz, J.F.; Pérez-Rojas, J.M. Effect of pinocembrin isolated from Mexican brown propolis on diabetic nephropathy. Molecules 2018, 23, 852. [CrossRef]

29. Costa, P.; Almeida, M.O.; Lemos, M.; Arruda, C.; Casoti, R.; Somensi, L.B.; Boeing, T.; Mariott, M.; Stein, B.D.P.; de Souza, P. Artepillin C, drupanin, aromadendrin-4′-O-methyl-ether and kaempferide from Brazilian green propolis promote gastroprotective action by diversified mode of action. J. Ethnopharmacol. 2018, 226, 82–89. [CrossRef]

30. Rojczyk, E.; Klama-Baryła, A.; Łabuś, W.; Wilemska-Kucharzewska, K.; Kucharzewski, M. Historical and modern research on propolis and its application in wound healing and other fields of medicine and contributions by Polish studies. J. Ethnopharmacol. 2020, 262, 113159. [CrossRef] [PubMed]

31. Governa, P.; Cusi, M.G.; Borgonetti, V.; Sforzin, J.M.; Terroso, C.; Baini, G.; Miraldi, E.; Biagi, M. Beyond the biological effect of a phytopharmaceutical: Artepillin C, drupanin, aromadendrin-4′-O-methyl-ether and kaempferide from Brazilian green propolis and the healing efficacy of Artepillin C. Biomed. Pharmacother. 2019, 112, 1094–1099. [CrossRef] [PubMed]

32. Refaat, H.; Mady, F.M.; Sarhan, H.A.; Rateb, H.S.; Alaaeldin, E. Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19. Int. J. Pharm. 2020, 120028. [CrossRef]

33. Granados-Pineda, J.; Uribe-Uribe, N.; García-López, P.; Ramos-Godínez, M.D.P.; Rivero-Cruz, J.F.; Pérez-Rojas, J.M. Effect of pinocembrin isolated from Mexican brown propolis on diabetic nephropathy. Molecules 2018, 23, 852. [CrossRef]

34. Costa, P.; Almeida, M.O.; Lemos, M.; Arruda, C.; Casoti, R.; Somensi, L.B.; Boeing, T.; Mariott, M.; Stein, B.D.P.; de Souza, P. Artepillin C, drupanin, aromadendrin-4′-O-methyl-ether and kaempferide from Brazilian green propolis promote gastroprotective action by diversified mode of action. J. Ethnopharmacol. 2018, 226, 82–89. [CrossRef] [PubMed]

35. Anjum, S.I.; Ullah, A.; Khan, K.A.; Attaullah, M.; Khan, H.; Ali, H.; Bashir, M.A.; Tahir, M.; Ansari, M.J.; Ghrامh, H.A. Composition and functional properties of propolis (bee glue): A review. J. Ethnopharmacol. 2019, 230, 1–19. [CrossRef] [PubMed]
41. Berretta, A.A.; Silveira, M.A.D.; Condor Capcha, J.M.; De Jong, D. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease. Running title: Propolis against SARS-CoV-2 infection and COVID-19. Biomed. Pharmacother. 2020, 131, 110622. [CrossRef] [PubMed]

42. Chu, Y.; Lv, X.; Zhang, L.; Fu, X.; Song, S.; Su, A.; Chen, D.; Xu, L.; Wang, Y.; Wu, Z.; et al. Wogonin inhibits in vitro herpes simplex virus type 1 and 2 infection by modulating cellular NF-kB and MAPK pathways. BMC Microbiol. 2020, 20, 227. [CrossRef] [PubMed]

43. Yildirim, A.; Duran, G.G.; Duran, N.; Jenedi, K.; Bolgul, B.S.; Miraloglou, M.; Muz, M. Antiviral activity of hatay propolis against replication of herpes simplex virus type 1 and 2. Pharm. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2016, 22, 422–430. [CrossRef]

44. Mazia, R.S.; de Araujo Pereira, R.R.; de Francisco, L.M.B.; Natali, M.R.M.; Dias Filho, B.P.; Nakamura, C.V.; Bruschi, M.L.; Ueda-Nakamura, T. Formulation and evaluation of a mucoadhesive thermo-responsive system containing Brazilian green propolis for the treatment of lesions caused by herpes simplex type 1. J. Pharm. Sci. 2016, 105, 113–121. [CrossRef]

45. Sartori, G.; Pesarico, A.P.; Pinton, S.; Dobrachinski, F.; Roman, S.S.; Paulotto, F.; Rodrigues, L.C.; Prigol, M. Protective effect of brown Brazilian propolis against acute vaginal lesions caused by herpes simplex virus type 2 in mice: Involvement of antioxidant and anti-inflammatory mechanisms. Cell Biochem. Funct. 2012, 30, 1–10. [CrossRef] [PubMed]

46. Nolker, S.; Reichling, J.; Sensch, K.H.; Schnitzler, P. Mechanism of herpes simplex virus type 2 suppression by propolis extracts. Phytomedicine 2010, 17, 132–138. [CrossRef]

47. Bankova, V.; Galabov, A.S.; Antonova, D.; Vihelmonova, N.; Di Perri, B. Chemical composition of propolis extract ACF and activity against herpes simplex virus. Phytotherapy 2014, 21, 1432–1438. [CrossRef]

48. Bufalo, M.C.; Figueiredo, A.S.; De Sousa, J.P.B.; Candeias, J.M.G.; Bastos, J.K.; Sforcin, J.M. Anti-poliomyelitis virus of Bacharis dracunculifolia and propolis by cell viability determination and real-time PCR. J. Appl. Microbiol. 2009, 107, 1669–1680. [CrossRef]

49. Labská, K.; Plodková, H.; Pummannová, M.; Sensch, K.H. Antiviral activity of propolis special extract GH 2002 against Varicella zoster virus in vitro. Die Pharm. Int. J. Pharm. Sci. 2018, 73, 733–736.

50. Silva-Beltran, N.P.; Balderra-Carmona, A.P.; Umsza-Machado, B.A. Anti-HIV activity of Brazilian green and red propolis extracts on Enterovirus surrogates. Environ. Sci. Pollut. Res. 2020, 27, 28510–28517. [CrossRef] [PubMed]

51. Gekker, G.; Hu, S.; Spivak, M.; Lokensgard, J.R.; Peterson, P.K. Anti-HIV-1 activity of propolis in CD4+ lymphocyte and microglial cell cultures. J. Ethnopharmacol. 2005, 102, 158–163. [CrossRef]

52. Shimizu, T.; Hino, A.; Tsutsui, A.; Park, Y.K.; Watanabe, W.; Kurokawa, M. Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice. Antivir. Chem. Chemother. 2008, 19, 7–13. [CrossRef] [PubMed]

53. Bürquez, M.d.J.G.; Mosqueda, M.d.L.J.; Mendoza, H.R.; Zárate, C.I.S.; Miranda, L.C.; Sánchez, T.A.C. Protective effect of a Mexican propolis on MDBK cells exposed to a ujeszky’s disease virus (pseudorabies virus). African J. Tradit. Complement. Altern. Med. 2015, 12, 106–111. [CrossRef]

54. Laila, U.; Akram, M.; Shariati, M.A.; Hashmi, A.M.; Akhtar, N.; Tahir, I.M.; Munir, N.; Riaz, M.; Akhter, N.; et al. Role of medicinal plants in HIV/AIDS therapy. Clin. Exp. Pharmacol. Physiol. 2019, 46, 1063–1073. [CrossRef]

55. Ito, J.; Chang, F.-R.; Park, Y.K.; Ikegaki, M.; Kilgore, N.; Lee, K.-H. Anti-AIDS agents. 48. Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis. J. Nat. Prod. 2015, 78, 1278–1281. [CrossRef]

56. Bai, H.; Obuchi, M.; Yoshida, H.; Watanabe, W.; Tsutsui, S.; Park, Y.K.; Matsuno, K.; Yasakiwaka, K.; Kurokawa, M. In vitro and in vivo anti-influenza virus activities of flavonoids and related compounds as components of Brazilian propolis (AP-08). J. Funct. Foods 2014, 8, 214–223. [CrossRef]

57. Erukhimovitch, V.; Talyshinsky, M.; Souprun, Y.; Huleihel, M. Spectroscopic investigation of herpes simplex virus infected cells and their response to antiviral therapy. J. Mol. Struct. 2020, 1131, 739–744. [CrossRef]

58. Bachevski, D.; Demailva, K.; Simeonovski, V.; Dimova, M. Back to the basics: Propolis and COVID-19. Dermatol. Ther. 2020, 33, e13780. [CrossRef] [PubMed]

59. Keni, R.; Alexander, A.; Nayak, P.G.; Mudgal, J.; Nandakumar, K. COVID-19: Emergence, spread, possible treatments, and global burden. Front. Public Health 2020, 8, 216–228. [CrossRef]

60. Khalifa, S.A.M.; Mohamed, B.S.; Elshal, M.H.; Du, M.; Guo, Z.; Zhao, C.; Musharraf, S.G.; Boskabady, M.H.; El-Seedi, H.H.R.; Efferth, T.; et al. Comprehensive overview on multiple strategies fighting COVID-19. Int. J. Environ. Res. Public Health 2020, 17, 5813. [CrossRef] [PubMed]

61. Beigel, J.H.; Tomashke, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; et al. Remdesivir for the treatment of Covid-19—Final report. N. Engl. J. Med. 2020, 383, 1813–1826. [CrossRef]

62. Khalifa, S.A.M.; Yosri, N.; El-Mallah, M.F.; Ghonaim, R.; Guo, Z.; Musharraf, S.G.; Du, M.; Khatib, A.; Xiao, J.; Saeed, A.; et al. Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic. Phytomedicine 2020, 85, 153311–153333. [CrossRef]

63. Maruta, H.; He, H. PAK1-blockers: Potential therapeutics against COVID-19. Med. Drug Discov. 2020, 6, 100039. [CrossRef]
67. Chiow, K.H.; Phoon, M.C.; Putti, T.; Tan, B.K.H.; Chow, V.T. Evaluation of antiviral activities of Houttuynia cordata Thumb. extract, quercetin, quercetrin and cinanerpin on murine coronavirus and dengue virus infection. Asian Pac. J. Trop. Med. 2016, 9, 1–7. [CrossRef]

68. Colunga Biancataelli, R.M.L.; Berrill, M.; Catravas, J.D.; Marik, P.E. Quercetin and vitamin c: An experimental, synergistic therapy for the prevention and treatment of sars-cov-2 related disease (COVID-19). Front. Immunol. 2020, 11, 1451. [CrossRef] [PubMed]

69. Sforcin, J.M. Propolis and the immune system: A review. J. Ethnopharmacol. 2007, 113, 1–14. [CrossRef]

70. Piñeros, A.R.; de Lima, M.H.F.; Rodrigues, T.; Gembre, A.F.; Bertolini, T.B.; Fonseca, M.D.; Berretta, A.A.; Ramalho, L.N.Z.; Cunha, F.Q.; Horti, J.I.; et al. Green propolis increases myeloid suppressor cells and CD4+Foxp3+ cells and reduces Th2 inflammation in the lungs after allergen exposure. J. Ethnopharmacol. 2020, 252, 112496. [CrossRef] [PubMed]

71. Lambrechts, B.N.; Hammad, H. Asthma: The importance of dysregulated barrier immunity. Eur. J. Immunol. 2013, 43, 3125–3137. [CrossRef] [PubMed]

72. Robinson, D.S.; Hamid, Q.; Ying, S.; Tsicopoulos, A.; Barkans, J.; Bentley, A.M.; Corrigan, C.; Durham, S.R.; Kay, A.B. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 1992, 326, 298–304. [CrossRef]

73. Sy, L.B.; Wu, Y.-L.; Chiang, B.-L.; Wang, Y.-H.; Wu, W.-M. Propolis extracts exhibit an immunoregulatory activity in an OVA-sensitized airway inflammatory animal model. Int. Immunopharmacol. 2006, 6, 1053–1060. [CrossRef]

74. Athari, S.S. Targeting cell signaling in allergic asthma. Signal Transduct. Target. Ther. 2019, 4, 45. [CrossRef]

75. Tanaka, M.; Okamoto, Y.; Fukui, T.; Masuzawa, T. Suppression of interleukin 17 production by Brazilian propolis in mice with collagen-induced arthritis. Inflammopharmacology 2012, 20, 19–26. [CrossRef]

76. Van den Berg, W.B.; Miossec, P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5, 549–553. [CrossRef] [PubMed]

77. Roeleved, D.M.; Koenders, M.I. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. Cytokine 2015, 74, 101–107. [CrossRef]

78. Okamoto, Y.; Tanaka, M.; Fukui, T.; Masuzawa, T. Brazilian propolis inhibits the differentiation of Th17 cells by inhibition of interleukin-6-induced phosphorylation of signal transducer and activator of transcription 3. Immunopharmacol. Immunotoxicol. 2012, 34, 803–809. [CrossRef]

79. Choi, J.-H.; Roh, K.-H.; Oh, H.; Park, S.-J.; Ha, S.-M.; Kang, M.S.; Lee, J.-H.; Jung, S.Y.; Song, H.; Yang, J.W.; et al. Caffeic acid phenethyl ester lessens disease symptoms in an experimental autoimmune uveoretinitis mouse model. Exp. Eye Res. 2015, 134, 53–62. [CrossRef] [PubMed]

80. Akira, S.; Takeda, K.; Kaisho, T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2, 679–686. [CrossRef] [PubMed]

81. Orsatti, C.L.; Sforcin, J.M. Propolis immunomodulatory activity on TLR-2 and TLR-4 expression by chronically stressed mice. Nat. Prod. Res. 2012, 26, 446–453. [CrossRef]

82. Búfalo, M.C.; Bordon-Graciani, A.P.; Conti, B.J.; de Assis Golim, M.; Sforcin, J.M. The immunomodulatory effect of propolis on receptors expression, cytokine production and fungicidal activity of human monocytes. J. Pharm. Pharmacol. 2014, 66, 1497–1504. [CrossRef] [PubMed]

83. Conti, B.J.; Búfalo, M.C.; Golim, M.d.A.; Bankova, V.; Sforcin, J.M. Cinnamic acid is partially involved in propolis immunomodulatory action on human monocytes. Evid. Based Complement. Altern. Med. 2013, 2013, 109864. [CrossRef]

84. Orsatti, C.L.; Missima, F.; Pagliarone, A.C.; Bachiega, T.F.; Búfalo, M.C.; Araújo, J.P., Jr.; Sforcin, J.M. Propolis immunomodulatory action in vivo on Toll-like receptors 2 and 4 expression and on pro-inflammatory cytokines production in mice. Phyther. Res. 2010, 24, 1141–1146. [CrossRef]

85. Conti, B.J.; Santiago, K.B.; Cardoso, E.O.; Freire, P.P.; Carvalho, R.F.; Golim, M.A.; Sforcin, J.M. Propolis modulates miRNAs involved in TLR-4 pathway, NF-kB activation, cytokine production and in the bactericidal activity of human dendritic cells. J. Pharm. Pharmacol. 2016, 68, 1604–1612. [CrossRef]

86. Búfalo, M.C.; Sforcin, J.M. The modulatory effects of caffeic acid on human monocytes and its involvement in propolis action. J. Pharm. Pharmacol. 2015, 67, 740–745. [CrossRef]

87. Pontin, K.; Da Silva Filho, A.A.; Santos, F.F.; e Silva, M.L.A.; Cunha, W.R.; Nanayakkara, N.P.D.; Bastos, J.K.; de Albuquerque, S. In vitro and in vivo antileishmanial activities of a Brazilian green propolis extract. Parasitol. Res. 2008, 103, 487–492. [CrossRef]

88. Da Silva, S.S.; Thomé, G.D.S.; Cateaneo, A.H.D.; Miranda, M.M.; Felipe, I.; Andrade, C.G.T.d.J.; Watanabe, M.A.E.; Piana, G.M.; Sforcin, J.M.; Pavanelli, W.R.; et al. Brazilian propolis antileishmanial and immunomodulatory effects. Evidence-Based Complement. Altern. Med. 2013, 2013, 673058. [CrossRef]

89. Amarante, M.K.; Watanabe, M.A.E.; Conchon-Costa, I.; Fiori, L.L.; Oda, J.M.M.; Búfalo, M.C.; Sforcin, J.M. The effect of propolis on CCL5 and IFN-γ expression by peripheral blood mononuclear cells from leishmaniasis patients. J. Pharm. Pharmacol. 2012, 64, 154–160. [CrossRef]

90. Don Santos Thomazelli, A.P.F.; Tomiottoto-Pellisser, F.; da Silva, S.S.; Panis, C.; Orsini, T.M.; Cateaneo, A.H.D.; Miranda-Sapla, M.M.; Custódio, L.A.; Tatakihara, V.L.H.; Bordignon, J.; et al. Brazilian propolis promotes immunomodulation on human cells from American Tegumentar Leishmaniasis patients and healthy donors infected with L. braziliensis. Cell. Immunol. 2017, 311, 22–27. [CrossRef]
91. Benkovic, V.; Horvat Knezevic, A.; Brozovic, G.; Knezevic, F.; Dikic, D.; Bevanda, M.; Basic, I.; Orsolic, N. Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on Ehrlich ascites tumor in mice. *Biomed. Pharmacother.* 2007, 61, 292–297. [CrossRef]

92. Oršolić, N.; Benković, V.; Lišićić, D.; Dikić, D.; Erhardt, J.; Horvat Knežević, A. Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan. *Med. Oncol.* 2010, 27, 1346–1358. [CrossRef]

93. Oršolić, N.; Bašić, I. Immunomodulation by water-soluble derivative of propolis: A factor of antitumor reactivity. *J. Ethnopharmacol.* 2003, 84, 265–273. [CrossRef]

94. Oršolić, N.; Bašić, I. Water-soluble derivative of propolis and its polyphenolic compounds enhance tumoricidal activity of macrophages. *J. Ethnopharmacol.* 2005, 102, 37–45. [CrossRef] [PubMed]

95. Oršolić, N.; Terzic, S.; Šver, L.; Bašić, I. Polyphenolic compounds from propolis modulate immune responses and increase host resistance to tumour cells. *Agric. Immunol.* 2005, 16, 165–179. [CrossRef]

96. Pagliarone, A.C.; Missima, F.; Bachiega, T.F.; Sforcin, J.M. The effects of propolis and its isolated compounds on cytokine production by murine macrophages. *Phyther. Res.* 2013, 27, 129–134. [CrossRef]

97. Girgin, G.; Baydar, T.; Ledochowski, M.; Schennach, H.; Bolukbasi, D.N.; Sorkun, K.; Salih, B.; Sahin, G.; Fuchs, D. Immunomodulatory effects of Turkish propolis: Changes in neopterin release and tryptophan degradation. *J. Ethnopharmacol.* 1995, 47, 145–147. [CrossRef]

98. Asgharpour, F.; Moghadamnia, A.A.; Motallebnejad, M.; Nouri, H.R. Propolis attenuates lipopolysaccharide-induced inflammatory responses in mice. *Vet. Res. Commun.* 2004, 26, 1469–1481. [CrossRef]

99. Medjeber, O.; Touri, K.; Rafa, H.; Djeraiba, Z.; Belkhelfa, M.; Boutaleb, A.F.; Belguendouz, H.; Touil-Boukoffa, A.S.; Vidor, T. Immunomodulation produced by a green propolis extract on humoral and cellular responses of mice immunized with SuHV-1. *Vaccine* 2007, 25, 1250–1256. [CrossRef] [PubMed]

100. Khosravi, A.R.; Shokri, H.; Darvishi, S.; Taghavi, M. Immunomodulatory efficacy of ethanol extract of propolis on tumor-bearing mice with disseminated candidiasis. *J. Mycol. Med.* 2014, 24, e143–e148. [CrossRef]

101. Touzani, S.; Embaslat, W.; Imtara, K.; Kmail, A.; ElArabi, I.; Badiaa, L.; Saad, B. In vitro evaluation of the potential use of propolis as a multitarget therapeutic product: Physicochemical properties, chemical composition, and immunomodulatory, antibacterial, and anticancer properties. *Biomed. Res. Int.* 2019, 2019, 4836378. [CrossRef] [PubMed]

102. Asgharpour, F.; Moghadamnia, A.A.; Motallebnejad, M.; Nouri, H.R. Propolis attenuates lipopolysaccharide-induced inflammatory responses in mice. *Vet. Res. Commun.* 2004, 26, 1469–1481. [CrossRef]

103. Conti, B.J.; Santiago, K.B.; Bufalo, M.C.; Herrera, Y.F.; Alday, E.; Velazquez, C.; Hernandez, J.; Sforcin, J.M. Modulatory effects of propolis samples from Latin America (Brazil, Cuba and Mexico) on cytokine production by human monocytes. *J. Pharm. Pharmacol.* 2015, 67, 1431–1438. [CrossRef]

104. Ivanovska, N.D.; Dimov, V.B.; Bankova, V.S.; Popov, S.S. Immunomodulatory action of propolis. VI. Influence of a water soluble derivative on complement activity in vivo. *J. Ethnopharmacol.* 1995, 47, 145–147. [CrossRef]

105. Girgin, G.; Baydar, T.; Ledaçñówski, M.; Schennach, H.; Bolukbasi, D.N.; Sorkun, K.; Salih, B.; Sahin, G.; Fuchs, D. Immunomodulatory effects of Turkish propolis: Changes in neopterin release and tryptophan degradation. *Immunobiology* 2009, 214, 129–134. [CrossRef] [PubMed]

106. Bachiega, T.F.; Orsatti, C.L.; Pagliarone, A.C.; Sforcin, J.M. The effects of propolis and its isolated compounds on cytokine production by murine macrophages. *Phyther. Res.* 2012, 26, 1308–1313. [CrossRef]

107. Machado, J.L.; Assunção, A.K.M.; da Silva, M.C.P.; dos Reis, A.S.; Costa, G.C.; Arruda, D.d.S.; Rocha, B.A.; Vaz, M.M.d.O.L.L.; Paes, A.M.d.A.; Guerra, R.N.M.; et al. Brazilian green propolis: Anti-inflammatory property by an immunomodulatory activity. *Evidence-Based Complement. Altern. Med.* 2012, 2012, 157652. [CrossRef]

108. Pagliarone, A.C.; Missima, F.; Orsatti, C.L.; Bachiega, T.F.; Sforcin, J.M. Proopioscin effect on Th1/Th2 cytokines production by acutely stressed mice. *J. Ethnopharmacol.* 2009, 125, 230–233. [CrossRef]

109. Pagliarone, A.C.; Missima, F.; Orsatti, C.L.; Bachiega, T.F.; Sforcin, J.M. Propolis effect on Th1/Th2 cytokine production by acutely stressed mice. *J. Ethnopharmacol.* 2009, 125, 230–233. [CrossRef]

110. Pagliarone, A.C.; Orsatti, C.L.; Missima, F.; Bašić, I. Immunomodulatory and antimitastatic action of propolis and related polyphenolic compounds. *J. Ethnopharmacol.* 2004, 94, 307–315. [CrossRef] [PubMed]
Foods 2021, 10, 1776

115. Só-Nunes, A.; Faccioli, L.H.; Sforcin, J.M. Propolis: Lymphocyte proliferation and IFN-γ production. J. Ethnopharmacol. 2003, 87, 93–97. [CrossRef]

116. Oršolić, N.; Šaranović, A.B.; Bašić, I. Direct and indirect mechanism(s) of antitumour activity of propolis and its polyphenolic compounds. Planta Med. 2006, 72, 20–27. [CrossRef] [PubMed]

117. Missima, F.; Sforcin, J.M. Green brazilian propolis action on macrophages and lymphoid organs of chronically stressed mice. Evid. Based Complement. Altern. Med. 2008, 5, 973715. [CrossRef] [PubMed]

118. Dimov, V.; Ivanovska, N.; Manolova, N.; Bankova, V.; Nikolov, N.; Popov, S. Immunomodulatory action of propolis. Influence on anti-infectious protection and macrophage function. Apidologie 1991, 22, 155–162. [CrossRef]

119. Orsolic, N.; Sver, L.; Terzic, S.; Tadic, Z.; Basic, I. Inhibitory effect of water-soluble derivative of propolis and its polyphenolic compounds on tumor growth and metastasizing ability: A possible mode of antitumor action. Nutr. Cancer 2003, 47, 156–163. [CrossRef]

120. Dantas, A.P.; Olivieri, B.P.; Gomes, F.H.M.; De Castro, S.L. Treatment of Trypanosoma cruzi-infected mice with propolis promotes changes in the immune response. J. Ethnopharmacol. 2006, 103, 187–193. [CrossRef]

121. Münstedt, K. Bee products and the treatment of blister-like lesions around the mouth, skin and genitalia caused by herpes viruses—a systematic review. Complement. Ther. Med. 2019, 43, 81–84. [CrossRef]

122. Vynograd, N.; Vynograd, I.; Sosnowski, Z. A comparative multi-centre study of the efficacy of propolis, acyclovir and placebo in the treatment of genital herpes (HSV). Phytomedicine 2000, 7, 1–6. [CrossRef]

123. Tomanova, D.; Holcova, S.; Hladikova, M. Clinical study: Lotion containing propolis special extract GH 2002 0.5% vs. placebo as on-top treatment of herpes zoster. Health (Irvine. Calif) 2017, 9, 1337–1347. [CrossRef]

124. Adis Insight. GH 2002; Propolis Extract; Propolis Special Extract. Available online: https://adisinsight.springer.com (accessed on 20 June 2021).

125. Holcová, S.; Hladíková, M. Efficacy and tolerability of propolis special extract GH 2002 as a lip balm against herpes labialis: A randomized, double-blind three-arm dose finding study. Health (Irvine. Calif) 2011, 3, 49–55. [CrossRef]

126. Arenberger, P.; Arenbergerova, M.; Hladíková, M.; Holcova, S.; Ottillinger, B. Comparative study with a lip balm containing 0.5% Propolis special extract GH 2002 versus 5% aciclovir cream in patients with herpes labialis in the papular/erythematous stage: A single-blind, randomized, two-arm study. Curr. Ther. Res. 2018, 88, 1–7. [CrossRef]

127. Jautová, J.; Zelenková, H.; Drotrarová, K.; Nejdková, A.; Grünwaldová, B.; Hladíková, M. Lip creams with propolis special extract GH 2002 0.5% versus aciclovir 5.0% for herpes labialis (vesicular stage). Wien. Med. Wochenschr. 2019, 169, 193–201. [CrossRef]

128. Scully, C. Propolis: A background. Br. Dent. J. 2006, 200, 359–360. [CrossRef] [PubMed]

129. Kandeel, M.; Abdelrahman, A.H.M.; Oh-Hashi, K.; Ibrahim, A.; Venugopala, K.N.; Morsy, M.A.; Ibrahim, M.A.A. Repurposing of FDA-approved antivirals, antibiotics, antihelminthic, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. J. Biomol. Struct. Dyn. 2020, 1–8. [CrossRef] [PubMed]

130. Mohamed, T.A.; Elshamy, A.I.; Ibrahim, M.A.A.; Zellagui, A.; Moustafa, M.F.; Abdelrahman, A.H.M.; Ohta, S.; Pare, P.W.; Hegazy, M.-E.F. Carotane sesquiterpenes from Ferula vesicertis: In silico analysis as SARS-CoV-2 binding inhibitors. Rsc Adv. 2020, 10, 34541–34548. [CrossRef]

131. Ibrahim, M.A.A.; Moustafa, M.F.; Abdelrahman, A.H.M.; Allemail, K.S.; Moustafa, M.F.; Shawky, A.M.; Mahzari, A.; Hakami, A.R.; Abdeljawaad, K.A.A.; Atia, M.A.M. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study. J. Mol. Graph. Model. 2021, 105, 107904. [CrossRef]

132. Ibrahim, M.A.A.; Abdelrahman, A.H.M.; Hussien, T.A.; Badr, E.A.A.; Mohamed, T.A.; El-Seedi, H.R.; Pare, P.W.; Efferth, T.; Hegazy, M.-E.F. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Comput. Biol. Med. 2020, 126, 104046. [CrossRef]

133. Ibrahim, M.A.A.; Abdelrahman, A.H.M.; Hegazy, M.-E.F. In-silico Drug Repurposing and Molecular Dynamics Puzzled out Potential SARS-CoV-2 Main Protease Inhibitors. Available online: https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1791958 (accessed on 29 July 2021).

134. Ibrahim, M.A.A.; Abdelrahman, A.H.M.; Allemail, K.S.; Almatroudi, A.; Moustafa, M.F.; Hegazy, M.-E.F. In silico evaluation of prospective anti-Covid-19 drug candidates as potential SARS-COV-2 main protease inhibito. Protein J. 2021, 40, 296–309. [CrossRef]

135. Ibrahim, M.A.A.; Abdeljawaad, K.A.A.; Abdelrahman, A.H.M.; Hegazy, M.-E.F. Natural-like products as potential SARS-CoV-2 Mpro inhibitors: In-silico drug discovery. J. Biomol. Struct. Dyn. 2020, 1–13. [CrossRef] [PubMed]

136. Ibrahim, M.A.A.; Abdelrahman, A.H.M.; Mohamed, T.A.; Atia, M.A.M.; Al-Hammady, M.A.M.; Abdeljawaad, K.A.A.; Elkady, E.M.; Moustafa, M.F.; Alrumaihi, F.; Allemail, K.S.; et al. In silico mining of terpenes from red-sea invertebrates for sars-cov-2 main protease (Mpro) inhibitors. Molecules 2021, 26, 2082. [CrossRef]

137. Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020, 582, 289–293. [CrossRef] [PubMed]

138. Gao, Y.; Yan, L.; Huang, Y.; Liu, F.; Zhao, Y.; Cao, L.; Wang, T.; Sun, Q.; Ming, Z.; Zhang, L.; et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science (80-): 2020, 368, 779–782. [CrossRef]

139. Osipiuk, J.; Azizi, S.-A.; Dvorkin, S.; Endres, M.; Jedrzejczak, R.; Jones, K.A.; Kang, S.; Kathayat, R.S.; Kim, Y.; Lisnyak, V.G.; et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 2021, 12, 743. [CrossRef] [PubMed]
140. Lan, J.; Ge, J.; Yu, J.; Shan, S.; Zhou, H.; Fan, S.; Zhang, Q.; Shi, X.; Wang, Q.; Zhang, L.; et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 2020, 581, 215–220. [CrossRef]

141. Newman, J.A.; Douangamath, A.; Yazdani, S.; Yosaatmadja, Y.; Aimon, A.; Brandão-Neto, J.; Dunnett, L.; Gorrie-stone, T.; Skynner, R.; Fearon, D.; et al. Structure, Mechanism and Crystallographic Fragment Screening of the SARS-COV-2 NSP13 Helicase. *bioRxiv* 2021. Available online: https://www.biorxiv.org/content/10.1101/2021.03.15.435326v1.abstract (accessed on 29 July 2021).

142. Martí-Renom, M.A.; Stuart, A.C.; Fiser, A.; Sánchez, R.; Melo, F.; Sali, A. Comparative protein structure modeling of genes and genomes. *Annu. Rev. Biophys. Biomol. Struct.* 2000, 29, 291–325. [CrossRef] [PubMed]

143. Gordon, J.C.; Myers, J.B.; Folta, T.; Shoja, V.; Heath, L.S.; Onufriev, A. H++: A server for estimating pKa s and adding missing hydrogens to macromolecules. *Nucleic Acids Res.* 2005, 33, W368–W371. [CrossRef]

144. Forli, S.; Huey, R.; Pique, M.E.; Sanner, M.F.; Goodsell, D.S.; Olson, A.J. Computational protein–ligand docking and virtual drug screening with the AutoDock suite. *Nat. Protoc.* 2016, 11, 905–919. [CrossRef]

145. Hawkins, P.C.D.; Skillman, A.G.; Warren, G.L.; Ellingson, B.A.; Stahl, M.T. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the protein databank and cambridge structural database. *J. Chem. Inf. Model.* 2010, 50, 572–584. [CrossRef]

146. OMEGA 2.5.1.4 OpenEye Scientific Software. Available online: https://www.yumpu.com/en/document/view/19633413/omega-release-2514-openeye-scientific-software-inc (accessed on 29 July 2021).

147. Halgren, T.A. MMFF VI. MMFF94s option for energy minimization studies. *J. Comput. Chem.* 1999, 20, 720–729. [CrossRef]

148. Szybki 1.9.0.3; OpenEye Scientific Software: Santa Fe, NM, USA, 2016.

149. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* 2009, 30, 2785–2791. [CrossRef]

150. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity—A rapid access to atomic charges. *Tetrahedron* 1980, 36, 3219–3228. [CrossRef]

151. Cheng, F.; Li, W.; Zhou, Y.; Shen, J.; Wu, Z.; Liu, G.; Lee, P.W.; Tang, Y. AdmetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. *J. Chem. Inf. Model.* 2012, 52, 3099–3105. [CrossRef] [PubMed]